







 
 
  



<HTML>
<HEAD>
<TITLE>
	
	Control of Conformational Equilibria in the Human B2 Bradykinin Receptor. MODELING OF NONPEPTIDIC LIGAND ACTION AND COMPARISON TO THE RHODOPSIN STRUCTURE -- Marie et al. 276 (44): 41100 -- Journal of Biological Chemistry</TITLE>


	
<script language="JavaScript">
<!--

function SymError()
{
  return true;
}

window.onerror = SymError;

var SymRealWinOpen = window.open;

function SymWinOpen(url, name, attributes)
{
  return (new Object());
}

window.open = SymWinOpen;

//-->
</script>

<SCRIPT LANGUAGE="JavaScript">
	<!--
	function startTarget(windowname,wid,hei) {
	
	var dotpos = windowname.indexOf(".");
	if (dotpos > -1)
	{
	var tempwn = windowname.substring(0,dotpos) +
		windowname.substring(dotpos + 1, windowname.length);
	windowname = tempwn;
	}
	var sizestring = 'width=' + wid + ',height=' + hei;
	window.open('',windowname,'scrollbars,resizable,' + sizestring + '\'');
	}
	// -->
	</SCRIPT>




	<!-- has inhead tag -->
	
		 
	 
	<script language="JavaScript">
	<!--
	if ( top != self )
	{
		top.location.href = unescape(window.location.pathname);
	}
	//-->
	</script>
	
		
	
		<style type="text/css"><!--
table.content_box_outer_table {
	padding-left:10px;
	padding-bottom:5px;
	padding-top:0px;
	padding-right:0px;
	}

table.content_box_outer_table_in_sidebar_frame {
	padding-left:10px;
	padding-bottom:0px;
	padding-top:10px;
	padding-right:10px;
	}

table.content_box_inner_table {
	background-color:#f0f0f0;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:5px;
	}

table.content_box_pdfinframes {
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:4px;
	}

td.content_box_title_highlight {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#006699;
	font-size:120%;
	font-weight:bold;
	text-align:center;
	padding:1px;
	vertical-align:middle;
	}

td.content_box_title {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#828282;
	font-size:120%;
	font-weight:bold;
	padding:1px;
	text-align:center;
	vertical-align:middle;
	}

td.content_box_space_between_sections {
	padding-top:2px;
	}

td.content_box_arrow {
	text-align:right;
	padding-left:5px;
	padding-right:0px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_item {
	text-align:left;
	vertical-align:top;
	padding-left:3px;
	padding-right:5px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_pdfinframes_citation_cell {
	background-color:#ffffff;
	border:1px #000000 solid;
	padding:3px;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	text-align:left;
	}


font.openaccess {
	font-weight:bold;
	padding-left:3px;
	padding-right:3px;
	background-color:#ffffff;
	}
font.openaccess_open {
	color:#000000;
	}
font.openaccess_access {
	color:#cc0000;
	}
font.openaccess_oa {
	}
.content_box_openaccess_title {
	text-align:center;
	white-space:nowrap;
	background-color:#BABABA;
	}

--></style>

		
	<script language="javascript">
		<!-- 
	function popwin(url,wid,hei,fromtop,fromleft) {
		var winPref = "channelmode=no,toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=auto,resizable=no,width=" + wid + ",height=" + hei + ",top=" + fromtop + ",left=" + fromleft;
		window.open(url, "popwin", winPref);
	}
	// -->
	</script>

<meta name="robots" content="nofollow">
<META NAME="ROBOTS" CONTENT="NOARCHIVE"> 

</HEAD>
<BODY BGCOLOR="#FFFFFF" 
	
		
			
		
	>



<A NAME="top"><!-- null --></A>

	
	<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0">
	<TR>
		<TD VALIGN="BOTTOM" NOWRAP>
			<A TARGET="_top" STYLE="text-decoration: none" HREF="/"><IMG BORDER="0" WIDTH="220" HEIGHT="44" ALT="JBC" SRC="/icons/banner/title.gif"></A>
			<A HREF="/cgi/adclick/?ad=4168&adclick=true&url=http://www.asbmb.org/ASBMB/site.nsf/web/05CC98009FE2797C85256E8D006F5DB2%3FOpenDocument"><IMG SRC="/adsystem/graphics/jbc/1098385641.gif?ad=4168&adview=true" ALT="Integration and Organization of Signaling Pathways Meeting" BORDER="1" WIDTH="220" HEIGHT="40"></A><BR><IMG ALT="" WIDTH="1" HEIGHT="3" SRC="/icons/spacer.gif"><BR>
			
	<TABLE CELLPADDING="2" CELLSPACING="2" WIDTH="450">
	<TR>
		<TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">HOME</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/help/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">HELP</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/cgi/feedback"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">FEEDBACK</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/subscriptions/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">SUBSCRIPTIONS</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/contents-by-date.0.shtml"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">ARCHIVE</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/search.dtl"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">SEARCH</FONT></A></TD>
	    


<TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/content/vol276/issue44/index.shtml"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">TABLE OF CONTENTS</FONT></A></TD>




	</TR>
	</TABLE>
	</TD>
		<TD><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
		<TD VALIGN="BOTTOM">
	
	<TABLE CELLPADDING="0" CELLSPACING="1" BORDER="0" BGCOLOR="#000000"><TR>
	<FORM METHOD="GET" NAME="search" ACTION="/cgi/search"><INPUT TYPE="hidden" NAME="andorexactfulltext" VALUE="and"><INPUT TYPE="hidden" NAME="resourcetype" VALUE="1"><INPUT TYPE="hidden" NAME="disp_type" VALUE=""><INPUT TYPE="hidden" NAME="sortspec" VALUE="relevance"><TD ALIGN="CENTER" VALIGN="MIDDLE"> 
		<TABLE CELLPADDING="1" CELLSPACING="0" BORDER="0" BGCOLOR="#DBDBDB"> 
		<TR>
			<TD BGCOLOR="#006699"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
			<TD VALIGN="MIDDLE"  BGCOLOR="#006699" NOWRAP><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#FFFFFF"><EM>QUICK</EM> SEARCH:&nbsp;</FONT></STRONG></TD>
			<TD ALIGN="RIGHT" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A STYLE="text-decoration:none;color:#FFFFFF" HREF="/search.dtl"><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">&nbsp;[advanced]</FONT></A></TD>
			<TD BGCOLOR="#006699"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
		</TR><TR>
			<TD BGCOLOR="#DBDBDB"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
			<TD BGCOLOR="#DBDBDB" COLSPAN="2">
			<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0"> 
			<TR>
				<TD ALIGN="CENTER" VALIGN="BOTTOM"><INPUT TYPE="submit" STYLE="text-decoration:none;font-family:verdana,arial,helvetica;font-size:10px;font-weight:bold;color:#000000;background:#FFFFFF;" VALUE="Go"></TD>
				<TH ALIGN="LEFT" COLSPAN="2"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Author:<BR></FONT>
					<INPUT TYPE="text" NAME="author1" SIZE="9" MAXLENGTH="80" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TH>
				<TH ALIGN="LEFT" COLSPAN="3"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Keyword(s):<BR></FONT>
					<INPUT TYPE="text" NAME="fulltext" SIZE="16" MAXLENGTH="80" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TH>
			</TR><TR>
				<TH><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Year:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="pubdate_year" SIZE="4" MAXLENGTH="4" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
				<TH ALIGN="RIGHT"><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Vol:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="volume" SIZE="4" MAXLENGTH="10" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
				<TH><FONT SIZE="-2" FACE="verdana,arial,helvetica,sans-serif" COLOR="#000000">Page:&nbsp;</FONT></TH>
				<TD><INPUT TYPE="text" NAME="firstpage" SIZE="4" MAXLENGTH="10" VALUE="" STYLE="font-family:verdana,arial,helvetica;font-size:10px;"></TD>
			</TR> 
			</TABLE> </TD>
			<TD BGCOLOR="#DBDBDB"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"></TD>
		</TR>
		</TABLE></TD></FORM></TR></TABLE> 
	 
	</TD>
	</TR><TR>
		<TD COLSPAN="3"><IMG ALT="" WIDTH="2" HEIGHT="2" SRC="/icons/spacer.gif"><BR>







	
	

	





	
	
	
	 

	


	
	




				<FONT SIZE="-2" FACE="verdana,arial,helvetica">
	<NOBR><STRONG>Institution: Cornell University Medical College</STRONG></NOBR>
	<NOBR><A TARGET="_top" HREF="/cgi/login?uri=%2Fcgi%2Fcontent%2Ffull%2F276%2F44%2F41100">Sign In as Member/Non-Member</A></NOBR>
	
		
		
	
	
	</FONT>
	
 <!-- showauthstring -->
	<!-- INST -->
	<!-- INDV -->
        <!-- SPONSORED -->
	<!-- USER.PFA -->
	<!-- USER.PFABSAIC -->
	<!-- NOT GUEST -->
	

	


<HR ALIGN="LEFT" SIZE="1" COLOR="#000000" NOSHADE></TD>
	</TR>
	</TABLE>



















	






	
		
		
	 
 




		<FONT COLOR="#A70716"></FONT>
	
	<FONT SIZE=-1>Originally published In Press as  <A HREF="/cgi/content/abstract/M104875200v1">doi:10.1074/jbc.M104875200</A> on August 8, 2001</FONT>


	
		
		<P><FONT SIZE=-1>J. Biol. Chem., Vol. 276, Issue 44, 41100-41111, November 2, 2001</FONT><BR>
		
	

 

 
	  
		
	
		<table class="content_box_outer_table"
		 
			
				
					align="right"
				
			
		>
			<tr>
			<td>
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				
				<strong><a href="/cgi/content/abstract/276/44/41100">
				Abstract</a></strong>
				 					<img alt="" width="32" height="7" border="0" src="/icons/shared/toc/free.gif">
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	

	
	
	

	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="/cgi/reprint/276/44/41100">
		<strong>Full Text</strong> (PDF)</a>
				
			
		
		</strong>
		</td></tr>
	
	

	
	
	

	
	
	

	
	





	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	









	
		
	
		
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item"><strong>
			All Versions of this Article:<br>
		
			
					276/44/41100
				
		&nbsp;&nbsp;&nbsp;<font color="#006699"><em>most recent</em></font><br>
	

	
		
		
			<a href="/cgi/content/short/M104875200v1">
					M104875200v1</a>
			
		</strong></td></tr>
	

	





	

	 

	

	
	
		  
    

	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=jbc;276/44/41100&return_type=article&return_url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F44%2F41100">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=276/44/41100&return_type=article&return_url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F44%2F41100">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		










			
		
			
			
			
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
					<strong><a href="/cgi/citemap?id=jbc;276/44/41100">
					Citation Map</a></strong>
				</td></tr>
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/mailafriend?url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F44%2F41100&title=Control+of+Conformational+Equilibria+in+the+Human+B2+Bradykinin+Receptor.+MODELING+OF+NONPEPTIDIC+LIGAND+ACTION+AND+COMPARISON+TO+THE+RHODOPSIN+STRUCTURE">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="/cgi/search?qbe=jbc;M104875200&journalcode=jbc&minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11495910&link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="/cgi/citmgr?gca=jbc;276/44/41100">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	


	
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="#otherarticles">
				Cited by other online articles</a></strong>
			</td></tr>
		
	
		
	

	

		


	
	
	
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><A HREF="/misc/Copyright_Permission.shtml">Copyright Permissions</a></strong>
			</td></tr>
		

	

	






	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11495910&link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Marie+J&link_type=AUTHORSEARCH">
							Articles by Marie, J.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Bonnafous+JC&link_type=AUTHORSEARCH">
							Articles by Bonnafous, J.-C.</a></strong>
						</td></tr>
				
			
		

		
	






	






	
		

	

		
			
		











	




	</td></tr></table>
</td></tr></table> 

	











 





	
	
	
	
	
	
	
	
	
		<vardef id="TEXT">

<!--

   Pages created by the Electronic Press Engine from

		Atypon Systems, Inc.

   Visit http://www.atypon.com/

-->





<H2>
<FONT COLOR=A70716 SIZE=-1>

</FONT>

    Control of Conformational Equilibria in the Human
B<SUB>2</SUB> Bradykinin Receptor
    <BR>

<font size=-1><BR>MODELING OF NONPEPTIDIC LIGAND ACTION AND COMPARISON TO THE
RHODOPSIN STRUCTURE<A HREF="#FN150"><SUP>*</SUP></A></font>
</H2>



<STRONG>
<NOWRAP>
Jacky 
Marie<SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP>,<WBR>
Eric 
Richard<SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP>,<WBR>
Didier 
Pruneau<SUP>&#167;</SUP>,<WBR>
Jean-Luc 
Paquet<SUP>&#167;</SUP>,<WBR>
Christian 
Siatka<SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP>,<WBR>
Ren&eacute;e 
Larguier<SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP>,<WBR>
Cecilia 
Ponc&eacute;<SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP>,<WBR>
Philippe 
Vassault<SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP>,<WBR>
Thierry 
Groblewski<SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP><A HREF="#FN154"><SUP>&#182;</SUP></A>,<WBR>
Bernard 
Maigret<SUP><IMG SRC="/math/12pt/normal/scr/par.gif" ALIGN=BOTTOM ALT="||"></SUP>, and<WBR>
Jean-Claude 
Bonnafous<SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP><A HREF="#FN160"><SUP>**</SUP></A>
</NOWRAP>
</STRONG>
<P>
From <SUP><IMG SRC="/math/12pt/normal/Dagger.gif" ALIGN=BOTTOM ALT="Dagger "></SUP>&nbsp;INSERM U439, 70&nbsp;rue de Navacelles 34090&nbsp;Montpellier, the <SUP>&#167;</SUP>&nbsp;Laboratoires Fournier, 50&nbsp;rue de Dijon,
and <SUP><IMG SRC="/math/12pt/normal/scr/par.gif" ALIGN=BOTTOM ALT="||"></SUP>&nbsp;Laboratoire de Chimie th&eacute;orique, Universit&eacute; de
Nancy 1,&nbsp;54506&nbsp;Vandoeuvre-les-Nancy C&eacute;dex, 21121&nbsp;Daix
<P>
Received for publication, May 29,&nbsp;2001, and in revised form, July 17,&nbsp;2001
<P>






    
	
	    
	
	    
		
    
	
	    
	
    
	
	    
	
    
    
	
	    
	
    







<a name = "Abstract"><!-- comment for mosaic --></a>



<BR CLEAR=ALL><A NAME="Abstract"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;ABSTRACT</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>ABSTRACT</FONT>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">INTRODUCTION</A>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>

<P>A prototypic study of the molecular
mechanisms of  activation or inactivation of peptide hormone G
protein-coupled receptors<SUP> </SUP>was carried out on the human
B<SUB>2</SUB> bradykinin receptor. A detailed<SUP> </SUP>pharmacological
analysis of receptor mutants possessing either<SUP> </SUP>increased constitutive
activity or impaired activation or ligand<SUP> </SUP>recognition allowed us to
propose key residues participating in<SUP> </SUP>intramolecular interaction
networks stabilizing receptor inactive<SUP> </SUP>or active conformations:
Asn<SUP>113</SUP> and Tyr<SUP>115</SUP> (TM</A> III), Trp<SUP>256</SUP>
and Phe<SUP>259</SUP> (TM</A> VI), Tyr<SUP>295</SUP> (TM</A> VII) which are
homologous of the rhodopsin residues Gly<SUP>120</SUP>,
Glu<SUP>122</SUP>, Trp<SUP>265</SUP>, Tyr<SUP>268</SUP>, and
Lys<SUP>296</SUP>, respectively. An essential experimental finding was
the spatial<SUP> </SUP>proximity between Asn<SUP>113</SUP>, which is the
cornerstone of inactive conformations, and Trp<SUP>256</SUP> which
plays a subtle role in controlling the balance between<SUP> </SUP>active and
inactive conformations. Molecular modeling and mutagenesis<SUP> </SUP>data showed
that Trp<SUP>256</SUP> and Tyr<SUP>295</SUP> constitute, together
with Gln<SUP>288</SUP>, receptor contact points with original
nonpeptidic ligands. It<SUP> </SUP>provided an explanation for the ligand inverse
agonist behavior<SUP> </SUP>on the WT</A> receptor, with underlying restricted motions
of TMs<SUP> </SUP>III, VI, and VII, and its agonist behavior on the
Ala<SUP>113</SUP> and Phe<SUP>256</SUP> constitutively activated
mutants. These data on the B<SUB>2</SUB> receptor<SUP> </SUP>emphasize that
conformational equilibria are controlled in a coordinated<SUP> </SUP>fashion by
key residues which are located at strategic positions<SUP> </SUP>for several G
protein-coupled receptors. They are discussed in<SUP> </SUP>comparison with the
recently determined rhodopsin crystallographic<SUP> </SUP>structure.
<BR><BR CLEAR=ALL>




<TXT>
<A NAME="SEC0"><!-- comment for mosaic --></A>

    
    

    
    

    
    
	
	
	
<BR CLEAR=ALL><A NAME="Introduction"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;INTRODUCTION</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>INTRODUCTION</FONT>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>

    

<P>The understanding of the mechanisms of G-protein coupled receptor
(GPCR</A>)<SUP>1</SUP> activation has been
improved by numerous experimental supports<SUP> </SUP>to the existence of multiple
conformations, active or inactive<SUP> </SUP>(<A HREF="#B1">1</A>). Mutation-induced constitutive
activation phenomena have<SUP> </SUP>been widely exploited to dissect the
intramolecular interaction<SUP> </SUP>networks which stabilize inactive receptor
conformations (<A HREF="#B1">1</A>),<SUP> </SUP>including random mutagenesis approaches to get
deeper insight<SUP> </SUP>into the obvious complexity of these networks (<A HREF="#B2">2</A>,
<A HREF="#B3">3</A>).
</P>
<P>In a preceding work (<A HREF="#B4">4</A>) we evidenced constitutive activation of the
human B<SUB>2</SUB> bradykinin receptor induced by mutations of<SUP> </SUP>Asn<SUP>113</SUP> in TM</A> III and Trp<SUP>256</SUP> in TM</A> VI. The role
of this tryptophan residue, which is fairly<SUP> </SUP>conserved in the GPCR</A>
family, was suggested by our previous modeling<SUP> </SUP>studies of the
AT<SUB>1</SUB> receptor (<A HREF="#B5">5</A>) and the constitutive activation<SUP> </SUP>of the
Ala<SUP>113</SUP> mutant is reminiscent of previous observations for
the AT<SUB>1</SUB> receptor<SUP> </SUP>mutated at the homologous Asn (<A HREF="#B6">6</A>). The
exceptionally high constitutive<SUP> </SUP>activation of the Ala<SUP>113</SUP>
B<SUB>2</SUB> receptor demonstrated the crucial role of
Asn<SUP>113</SUP> in stabilizing an inactive B<SUB>2</SUB> receptor
conformation and the extreme<SUP> </SUP>conformational flexibility of this
receptor. This flexibility<SUP> </SUP>was further supported by the striking
changes in the pharmacological<SUP> </SUP>properties of peptidic or nonpeptidic
ligands induced by Asn<SUP>113</SUP> or Trp<SUP>256</SUP> mutations
(<A HREF="#B4">4</A>). These data make the B<SUB>2</SUB> receptor an interesting<SUP> </SUP>model
to study conformational changes associated to activation.<SUP> </SUP>In this
respect the original nonpeptidic ligands designed by Fournier<SUP> </SUP>Research
Laboratories, which constitute potential anti-inflammatory<SUP> </SUP>drugs (<A HREF="#B7">7</A>,
<A HREF="#B8">8</A>), turned out to be interesting tools to modulate<SUP> </SUP>conformational
equilibria. The purpose of the present work was<SUP> </SUP>to take advantage of
constitutive activation phenomena to delineate<SUP> </SUP>some features of
inactive receptor conformations and to propose<SUP> </SUP>a model of nonpeptide
antagonist interaction with the B<SUB>2</SUB> receptor.<SUP> </SUP>These models
are discussed with reference to those built for other<SUP> </SUP>GPCR</A> (<A HREF="#B9">9</A>, <A HREF="#B10">10</A>), the
recent crystallographic data for rhodopsin<SUP> </SUP>(<A HREF="#B11">11</A>) and current knowledge
about their activation processes.<SUP> </SUP>This study emphasizes the roles of
some key residues that are<SUP> </SUP>located at strategic positions for several
GPCR</A>, including rhodopsin,<SUP> </SUP>and simultaneously control ligand
recognition and conformational<SUP> </SUP>equilibria (Fig.
<a href="#F1">1</a>).



<BR CLEAR=ALL><A NAME="F1"><!-- FIG 1 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/44/41100/F1">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=200 HEIGHT=115 SRC="/content/vol276/issue44/images/small/bc4114724001.gif"></A><BR>

<STRONG>View larger version</STRONG> (36K):
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/F1">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/44/41100/F1"
onClick="startTarget('F1', 590, 453); this.href='/cgi/content-nw/full/276/44/41100/F1'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F1">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 1. &nbsp;</STRONG>

<B>Location and conservation in some </B><B>GPCR</B></A><B> of
residues playing key or switch roles in the B<SUB>2</SUB>
receptor.</B> Sequence comparisons of TMs II, III, VI, and VII of the
B<SUB>2</SUB> receptor with those of some other GPCR</A> reveal the
residues, located at privileged positions, which have been shown to be
involved in ligand binding or activation properties, or both. The
residues located in <I>boxes</I> have been experimentally shown to
be important for the function of a given receptor. The roles of the
mentioned B<SUB>2</SUB> receptor residues have been assessed in
previous works (<A HREF="#B4">4</A>, <A HREF="#B19">19</A>) or constitute the matter of the present
paper.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 1 -->




<BR><BR CLEAR=ALL>



<A NAME="SEC1"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;EXPERIMENTAL PROCEDURES</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>EXPERIMENTAL PROCEDURES</FONT>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">RESULTS</A>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>


    



    



    


<P><I>Reagents and Ligands--</I>

BK was purchased from Sigma,
<I>myo</I>-[2-<SUP>3</SUP>H] inositol and [<SUP>3</SUP>H]BK
(specific radioactivity about 100&nbsp;Ci/mmol) were purchased from <a href="/cgi/inline?Amersham%20Pharmacia%20Biotech">Amersham<SUP> </SUP>Pharmacia Biotech.</a> Hydroxyphenyl-propionyl-HOE 140&nbsp;(HPP-HOE 140)<SUP> </SUP>was
kindly supplied by Professor J.&nbsp;Martinez (CNRS, Montpellier,<SUP> </SUP>France);
it was radioiodinated using Na<SUP>125</SUP>I (2,000&nbsp;Ci/mmol) and
IODO-GEN as oxidizing agent. The nonpeptidic<SUP> </SUP>derivatives (Fig.
<a href="#F2">2</a>) were designed and synthesized by
Fournier<SUP> </SUP>Research Laboratories (Daix, France). COS-7 cells were from
the<SUP> </SUP>European Cell Type Collection (Salisbury, United Kingdom).



<BR CLEAR=ALL><A NAME="F2"><!-- FIG 2 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/44/41100/F2">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=198 HEIGHT=200 SRC="/content/vol276/issue44/images/small/bc4114724002.gif"></A><BR>

<STRONG>View larger version</STRONG> (23K):
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/F2">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/44/41100/F2"
onClick="startTarget('F2', 585, 640); this.href='/cgi/content-nw/full/276/44/41100/F2'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F2">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 2. &nbsp;</STRONG>

<B>Structure of nonpeptidic ligands specific of
the human B<SUB>2</SUB> bradykinin receptor.</B> The compounds LF
16-0335&nbsp;and LF 16-0687&nbsp;are quite similar: they possess the same
substituted quinoline at one extremity and a benzamidine moiety at the
other, the latter compound displaying a significantly higher affinity
for the receptor. LF 18-1300&nbsp;differs from LF 16-0687&nbsp;by the imidazole
substitution on the quinoline moiety, resulting in improved affinity.
LF 18-1833&nbsp;possesses the same imidazole-substituted quinoline, while
being shortened at its other extremity which no longer possesses the
benzamidine function.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 2 -->







    

    


<P><I>Site-directed Mutagenesis and Receptor Expression--</I>

The human
B<SUB>2</SUB> receptor sequence has been determined by Hess <I>et
al.</I> (<A HREF="#B12">12</A>). The WT</A> and mutated receptors were systematically<SUP> </SUP>tagged
through the addition of a 10-amino acid epitope from the<SUP> </SUP>c-<I>myc</I> oncogene at the N termini of receptors
truncated at the<SUP> </SUP>Asn<SUP>3</SUP> residue. The cDNA sequences
included a Kozak sequence. The various<SUP> </SUP>mutations were carried out as
described previously (<A HREF="#B4">4</A>). Receptors<SUP> </SUP>were transiently expressed in COS-7
cells using the electroporation<SUP> </SUP>transfection method (<A HREF="#B4">4</A>).
Pharmacological characterizations<SUP> </SUP>were performed on cells cultured for
2&nbsp;days at 37&nbsp;&#176;C in Dulbecco's<SUP> </SUP>modified Eagle's medium, 4.5&nbsp;g/liter
glucose, 10% fetal calf serum,<SUP> </SUP>100&nbsp;units/ml penicillin, 100&nbsp;units/ml<SUP> </SUP>streptomycin.



    

    


<P><I>Binding Assays--</I>

The binding of [<SUP>3</SUP>H]BK or
<SUP>125</SUP>I-HPP-HOE 140&nbsp;to crude membranes from transfected COS-7
cells was carried out as previously described<SUP> </SUP>(<A HREF="#B4">4</A>).
<P>
The binding of [<SUP>3</SUP>H]BK to intact cells (24&nbsp;or 48&nbsp;well
dishes), including evaluation of expression levels, and IP</A> production<SUP> </SUP>(12-well dishes) were routinely carried out as described in Ref.<SUP> </SUP><A HREF="#B4">4</A>. In
experiments devoted to the effects of Zn<SUP>2+</SUP> ions, the media
were modified to ensure their perfect solubility:<SUP> </SUP>[<SUP>3</SUP>H]BK
binding was carried out in 25&nbsp;m<font size=-1>M</font> HEPES, 140&nbsp;m<font size=-1>M</font>
NaCl, 140<SUP>&nbsp;</SUP>&#181;g/ml bacitracin, 10&nbsp;&#181;<font size=-1>M</font> captopril, pH 7.4; IP</A>
accumulation was<SUP> </SUP>measured in 20&nbsp;m<font size=-1>M</font> HEPES, 116&nbsp;m<font size=-1>M</font> NaCl, 11&nbsp;m<font size=-1>M</font> glucose, 2.5&nbsp;m<font size=-1>M</font>
CaCl<SUB>2</SUB>,<SUP> </SUP>4.7&nbsp;m<font size=-1>M</font> KCl, 140&nbsp;&#181;g/ml bacitracin, 10&nbsp;&#181;<font size=-1>M</font> captopril, pH 7.4.



    

    


<P><I>Molecular Modeling--</I>

Models were built on an "Octane"
Silicon Graphics computer, using software from Molecular Simulations
Inc. (Insight, Discover,<SUP> </SUP>Homology, Modeler). Molecular dynamics
simulations carried out<SUP> </SUP>in the absence of restraints of some
transmembrane helices were<SUP> </SUP>performed using the computing facilities of<SUP> </SUP>CINES.
<P>
The B<SUB>2</SUB> receptor "experimental model" was built using
the Modeler software, using as template a first AT<SUB>1</SUB>
receptor model (<A HREF="#B13">13</A>)<SUP> </SUP>in which the position of TM</A> VI has been refined
(about 30&#176; rotation)<SUP> </SUP>so as to fit pharmacological data relative to
losartan (<A HREF="#B5">5</A>).<SUP> </SUP>As compared with the AT<SUB>1</SUB> template a slight
rotation of helix VII<SUP> </SUP>was introduced to take into account binding
properties on nonpeptidic<SUP> </SUP>ligands to receptors mutated at some
positions of these helices<SUP> </SUP>(Thr<SUP>287</SUP> and
Gln<SUP>288</SUP>).
<P>
A second B<SUB>2</SUB> receptor model was built using the rhodopsin
crystallographic structure as template ("rhodopsin-like" model).<SUP> </SUP>For both models the positions of the transmembrane helix peptidic<SUP> </SUP>backbones were strictly ascribed to those of their respective<SUP> </SUP>templates
with the exception of transmembrane domains displaying<SUP> </SUP>differences in
proline residues: in the "rhodopsin-like model"<SUP> </SUP>the 35-48
(N-terminal part of TM</A> I) and 285-290 (N-terminal part<SUP> </SUP>of TM</A> VII)
sequences were ascribed to helix structures; in the<SUP> </SUP>experimental
model the 278-288 sequence was forced to an helix<SUP> </SUP>structure.
<P>
Molecular dynamics was initially applied to the conformational analysis
of LF 16-0687.&nbsp;The analysis of the corresponding trajectory<SUP> </SUP>revealed,
as expected, a great flexibility of the molecule. The<SUP> </SUP>lowest energy
conformations were compact, with an interaction<SUP> </SUP>between the quinoline
and benzamidine moieties. However, it appeared<SUP> </SUP>impossible to perform
any preliminary positioning of such conformations<SUP> </SUP>into our receptor
model. As a consequence we selected extended<SUP> </SUP>conformations and
performed their manual docking so as to fit<SUP> </SUP>the experimental<SUP> </SUP>data.
<P>
The quinoline of LF 16-0687&nbsp;or LF 18-1300&nbsp;was positioned so as to
interact simultaneously with Tyr<SUP>295</SUP> and Trp<SUP>256</SUP>.
Then the rest of the molecule was orientated toward the extracellular<SUP> </SUP>side of the TMs, applying appropriate torsion angles to the ligand<SUP> </SUP>bonds, with the exception of the dichlorophenyl-SO<SUB>2</SUB>-prolyl
portion<SUP> </SUP>which was considered as playing an essential orientation role;<SUP> </SUP>therefore the geometry of this portion was kept close to that<SUP> </SUP>delineated by the ligand conformational analysis. No remarkable<SUP> </SUP>interaction could be found for the dichloro-phenyl group of the<SUP> </SUP>ligand
which was positioned between TMs II and VII inside the<SUP> </SUP>intrahelix
space. Thr<SUP>287</SUP> and Gln<SUP>288</SUP> thus appeared as
possible candidates for an interaction with<SUP> </SUP>the carbonyl function of
the prolyl ligand moiety. As the mutation<SUP> </SUP>of Thr<SUP>287</SUP> to Ala
or Leu, its B<SUB>1</SUB> counterpart, had no incidence on affinity,<SUP> </SUP>we favored the existence of an hydrogen bond interaction between<SUP> </SUP>Gln<SUP>288</SUP> and the carbonyl group of the prolyl moiety and we
slightly rotated<SUP> </SUP>helix VII, by ~20&#176;, so as to fulfil this
interaction preference<SUP> </SUP>while preserving the "sandwich" interaction
of the quinoline with<SUP> </SUP>the Trp<SUP>256</SUP> and Tyr<SUP>295 </SUP>residues.



    


    


    
    


<BR><BR CLEAR=ALL>


<A NAME="SEC2"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;RESULTS</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>RESULTS</FONT>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">DISCUSSION</A>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>


    


<P ALIGN=CENTER><B>Strategy: Rationale of AT<SUB>1</SUB> and B<SUB>2</SUB> Receptor
Comparison</B>
</P>


    
    <P>Our previous modeling studies of the AT<SUB>1</SUB> receptor (<A HREF="#B5">5</A>,
<A HREF="#B13">13</A>) and experimental data revealed the essential roles of the conserved<SUP> </SUP>Asp in TM</A> II (Asp<SUP>74</SUP>), Asn<SUP>111</SUP> (TM</A> III), the
fairly conserved Trp in TM</A> VI (Trp<SUP>253</SUP>), His<SUP>256</SUP>
located one helix turn above Trp<SUP>253</SUP> and Tyr<SUP>292</SUP>
(TM</A> VII) which occupies a position homologous to that of the<SUP> </SUP>rhodopsin
Lys<SUP>296</SUP>, the site of retinal covalent binding. An inactive
receptor conformation<SUP> </SUP>would be stabilized by a double interaction of
Asn<SUP>111</SUP> (TM</A> III) with Tyr<SUP>292</SUP> (TM</A> VII) and
Trp<SUP>253</SUP> (TM</A> VI), homologous of the rhodopsin
Trp<SUP>265</SUP>; the Asn<SUP>111</SUP>-Trp<SUP>253</SUP> proximity
was postulated upon model refinement (helix VI rotation)<SUP> </SUP>(<A HREF="#B5">5</A>) to make it
consistent with the pharmacological properties<SUP> </SUP>of the nonpeptidic
ligand losartan (<A HREF="#B5">5</A>, <A HREF="#B14">14</A>). We postulated<SUP> </SUP>that the interaction of the
Tyr<SUP>4</SUP> residue of AII with Asn<SUP>111</SUP> would
destabilize the above mentioned network and induce rearrangements<SUP> </SUP>resulting in a Asp<SUP>74</SUP>-Tyr<SUP>292</SUP> interaction (<A HREF="#B13">13</A>)
and an intrahelical interaction between Trp<SUP>253</SUP> and
His<SUP>256</SUP>. The experimental supports can be summarized as
follows: receptor<SUP> </SUP>inactivation upon Y292F (<A HREF="#B15">15</A>), W253F (<A HREF="#B5">5</A>), and H256A
mutations<SUP> </SUP>(<A HREF="#B5">5</A>, <A HREF="#B16">16</A>); strong constitutive activation upon
Asn<SUP>111</SUP> mutations (<A HREF="#B6">6</A>, <A HREF="#B17">17</A>); detailed analysis of the
induction of<SUP> </SUP>intermediary or activated conformations (<A HREF="#B17">17</A>, <A HREF="#B18">18</A>).
Interestingly<SUP> </SUP>these residues are conserved in the B<SUB>2</SUB>
receptor, with the exception<SUP> </SUP>of His<SUP>256</SUP> which is replaced by
Phe<SUP>259</SUP>. That this latter residue is a BK interaction site
(proposed<SUP> </SUP>for the rat receptor (<A HREF="#B19">19</A>), and extended to the human receptor<SUP> </SUP>in the present work) and previous results demonstrating a role<SUP> </SUP>for
Asn<SUP>113</SUP> and Trp<SUP>256</SUP> (<A HREF="#B4">4</A>) reinforces the interest
of a mechanistic comparison of<SUP> </SUP>the AT<SUB>1</SUB> and B<SUB>2</SUB>
receptors which display a sequence identity similar<SUP> </SUP>to that of the
AT<SUB>1</SUB>/AT<SUB>2</SUB> or B<SUB>1</SUB>/B<SUB>2</SUB> pairs
(about 30%).
    
    


    
    </P>

    


<P ALIGN=CENTER><B>Role of Trp<SUP>256</SUP> in the Activation Process</B>
</P>


    
    <P>Our previous study (<A HREF="#B4">4</A>) showed that Trp<SUP>256</SUP> mutation to
Phe or Gln induced marked increases in the human B<SUB>2</SUB>
receptor constitutive<SUP> </SUP>activity, together with changes in the
pharmacological properties<SUP> </SUP>of the peptidic compound HOE 140&nbsp;and the
nonpeptidic ligand LF<SUP> </SUP>16-0335.&nbsp;We further investigated the crucial role
of Trp<SUP>256</SUP> by evaluating the activation properties of the
W256F, W256Q,<SUP> </SUP>and W256A mutant receptors, as well as the double mutants
displaying<SUP> </SUP>the additional Asn<SUP>113</SUP> to Ala<SUP> </SUP>mutation.
    </P>
    

    
    <P>Fig. <a href="#F3">3</a> shows that, at similar expression
levels, the W256F and W256Q mutants were significantly constitutively
activated (CAM</A><SUP> </SUP>receptors) as compared with the wild-type receptor, the
activation<SUP> </SUP>factor varying from 4&nbsp;to 10&nbsp;according to experiments.
Combined<SUP> </SUP>with the previously described exceptionally high constitutive<SUP> </SUP>activation displayed by the Ala<SUP>113</SUP> mutant (Fig. <a href="#F3">3</a>), we
postulated that inactive receptor conformation(s)<SUP> </SUP>might be
stabilized by an Asn<SUP>113</SUP>-Trp<SUP>256</SUP>
interaction.



<BR CLEAR=ALL><A NAME="F3"><!-- FIG 3 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/44/41100/F3">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=200 HEIGHT=153 SRC="/content/vol276/issue44/images/small/bc4114724003.gif"></A><BR>

<STRONG>View larger version</STRONG> (18K):
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/F3">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/44/41100/F3"
onClick="startTarget('F3', 590, 537); this.href='/cgi/content-nw/full/276/44/41100/F3'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F3">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 3. &nbsp;</STRONG>

<B>Basal </B><B>IP</B></A><B> production activities in </B><B>WT</B></A><B> or
mutant B<SUB>2</SUB> receptors.</B> The WT</A> and mutant receptor were
expressed at several mean levels, in the range 3&nbsp;&#215;&nbsp;10<SUP>5</SUP>-6&nbsp;&#215;&nbsp;10<SUP>5</SUP> sites/cell, as described
under "Experimental Procedures" and basal activities have been
compared for similar expression levels within each experiment. The
indicated values represent the mean of three to 10&nbsp;experiments.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 3 -->




    </P>
    

    
    <P>The first interesting finding was the lack of constitutive activation
of the W256A mutant, with preservation of the BK activation<SUP> </SUP>properties
(Fig. <a href="#F3">3</a>). This result has two implications: taking<SUP> </SUP>into account the
proximity of Asn<SUP>113</SUP> and Trp<SUP>256</SUP> (validated in
experiments described in the next paragraph) the<SUP> </SUP>hypothesis that
Asn<SUP>113</SUP> and Trp<SUP>256</SUP> might stabilize an inactive
conformation through interactions<SUP> </SUP>with separate unidentified partners
appeared unlikely as Trp to<SUP> </SUP>Ala mutation would be expected to be
activating in such a situation;<SUP> </SUP>the role of Trp<SUP>256</SUP> cannot
be restricted to an interaction with Asn<SUP>113</SUP> stabilizing an
inactive conformation. Trp<SUP>256</SUP> might also contribute to the
stabilization or the generation<SUP> </SUP>of an active conformation in which the
Asn<SUP>113</SUP>-Trp<SUP>256</SUP> interaction would be<SUP> </SUP>disrupted.
    </P>
    

    
    <P>One can reasonably postulate that Asn<SUP>113</SUP> and
Trp<SUP>256</SUP> belong to a network of concerted interactions
comprising one or several other<SUP> </SUP>residues and subtly tuned by the
residue at position 256.&nbsp;Constitutive<SUP> </SUP>activation observed upon Trp
mutation to Phe or Gln would then<SUP> </SUP>result from the perturbation of a
balance between these<SUP> </SUP>interactions.
    
    


    
    </P>

    


<P ALIGN=CENTER><B>Biochemical Verification of the
Asn<SUP>113</SUP>-Trp<SUP>256</SUP> Proximity</B>
</P>


    
    <P>Asn<SUP>113</SUP> and Trp<SUP>256</SUP> were substituted, either
separately or simultaneously, by histidine, and the binding of
Zn<SUP>2+</SUP> ions to the single or double His mutants was
evaluated. Results<SUP> </SUP>in Fig. <a href="#F4">4</a><I>A</I>
show that His mutations by themselves induce no or<SUP> </SUP>little perturbation
of BK or HOE 140&nbsp;recognition. Competition<SUP> </SUP>binding of Zn<SUP>2+</SUP>
ions using [<SUP>3</SUP>H]BK as tracer ligand revealed a striking
leftwards shift of the<SUP> </SUP>dose-response curve for the double N113H, W256H
mutant as compared<SUP> </SUP>with the WT</A> receptor (Fig. <a href="#F4">4</a>); it indicated an
increased affinity<SUP> </SUP>for Zn<SUP>2+</SUP> ions, interpreted as a spatial
proximity between the two histidines.<SUP> </SUP>This effect was not observed for
the W256H single mutant. It was<SUP> </SUP>much less pronounced for the N113H
single mutant; the slight shift<SUP> </SUP>observed in this case probably resulted
from the ability of Zn<SUP>2+</SUP> ions, which can display different
modes of interactions with<SUP> </SUP>amino acid side chains (<A HREF="#B20">20-22</A>), to
coordinate N113H to another<SUP> </SUP>residue. These results were confirmed by
functional assays which<SUP> </SUP>first indicated that His replacement of
Asn<SUP>113</SUP>, or Trp<SUP>256</SUP> or both induced neither
constitutive activation, nor modification<SUP> </SUP>of BK-stimulated IP</A>
production. Zn<SUP>2+</SUP> ions, which had no effect on basal
activities, were able to counteract<SUP> </SUP>BK-induced IP</A> production in COS-7
expressing the N113H, W256H<SUP> </SUP>mutant (Fig. <a href="#F4">4</a><I>B</I>), with
Zn<SUP>2+</SUP> inactivation characteristics similar to those observed
for BK<SUP> </SUP>binding.



<BR CLEAR=ALL><A NAME="F4"><!-- FIG 4 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/44/41100/F4">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=200 HEIGHT=123 SRC="/content/vol276/issue44/images/small/bc4114724004.gif"></A><BR>

<STRONG>View larger version</STRONG> (21K):
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/F4">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/44/41100/F4"
onClick="startTarget('F4', 590, 470); this.href='/cgi/content-nw/full/276/44/41100/F4'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F4">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 4. &nbsp;</STRONG>

<B>Histidine engineering and Zn<SUP>2+</SUP>
effects on BK binding and BK-induced </B><B>IP</B></A><B> production.</B>
Asn<SUP>113</SUP> or Trp<SUP>256</SUP> or both residues were mutated
to His and the WT</A> and mutant B<SUB>2</SUB> receptors were transiently
expressed in COS-7 cells as described under "Experimental
Procedures." Zn<SUP>2+</SUP> ion affinities for the various
receptors were indirectly evaluated by their ability to inhibit
[<SUP>3</SUP>H]BK binding (1&nbsp;n<font size=-1>M</font>) to intact cells
(<I>A</I>) or 0.5&nbsp;n<font size=-1>M</font> BK-induced IP</A> production
(<I>B</I>).


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 4 -->




    
    


    
    </P>

    


<P ALIGN=CENTER><B>Concerted Roles of Trp<SUP>256</SUP> and Asn<SUP>113</SUP> in the
Human B<SUB>2</SUB> Receptor Activation</B>
</P>


    
    <P>The pivotal role of Trp<SUP>256</SUP> was confirmed by the
pharmacological properties of B<SUB>2</SUB> receptors mutated at this
position. HOE 140,<SUP>&nbsp;</SUP>which behaved as an inverse agonist of the WT</A>
receptor in experimental<SUP> </SUP>situations where the basal IP</A> production is
high enough (<A HREF="#B4">4</A>),<SUP> </SUP>became a fairly potent agonist of the three W256F,
W256Q, and<SUP> </SUP>W256A mutant receptors, with a markedly decreased maximal
stimulation<SUP> </SUP>for the latter mutant (Fig.
<a href="#F5">5</a><I>A</I>). The binding of a
radioiodinated<SUP> </SUP>derivative of HOE 140&nbsp;(<SUP>125</SUP>I-HPP-HOE 140)
revealed moderate decreases in affinity for the<SUP> </SUP>mutant receptors (Table
<a href="#TI">I</a>). The behavior of the nonpeptidic
compound<SUP> </SUP>LF 16-0335&nbsp;was strikingly different: it only activated the
W256F<SUP> </SUP>mutant (Fig. <a href="#F5">5</a><I>B</I>). These properties of LF 16-0335&nbsp;were
reproduced<SUP> </SUP>for LF 16-0687,&nbsp;LF 18-1300,&nbsp;and LF 18-1833&nbsp;which were
agonists<SUP> </SUP>of the W256F mutant, and not of the W256Q and W256A mutants
(not<SUP> </SUP>shown). The <I>K</I><SUB><I>i</I></SUB> values relative to LF 16-0335&nbsp;and LF 16-0687,<SUP>&nbsp;</SUP>determined in competition binding assays using
<SUP>125</SUP>I-HPP-HOE 140&nbsp;as tracer ligand, were slightly increased
for the<SUP> </SUP>three mutants, the most significant increase being observed for<SUP> </SUP>the W256A receptor (Table <a href="#TI">I</a>). Similar data were obtained when<SUP> </SUP>[<SUP>3</SUP>H]BK was used as tracer ligand (not shown). These
results suggest<SUP> </SUP>that Trp<SUP>256</SUP> might directly interact with
the nonpeptidic ligand through an<SUP> </SUP>aromatic-aromatic interaction (which
does not exclude additional<SUP> </SUP>interactions such as hydrogen bonding or
amino-aromatic interactions)<SUP> </SUP>and that preservation of this interaction
in the W256F CAM</A> receptor<SUP> </SUP>participates to the ligand agonist behavior
(see paragraph devoted<SUP> </SUP>to modeling).



<BR CLEAR=ALL><A NAME="F5"><!-- FIG 5 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/44/41100/F5">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=127 HEIGHT=200 SRC="/content/vol276/issue44/images/small/bc4114724005.gif"></A><BR>

<STRONG>View larger version</STRONG> (18K):
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/F5">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/44/41100/F5"
onClick="startTarget('F5', 430, 640); this.href='/cgi/content-nw/full/276/44/41100/F5'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F5">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 5. &nbsp;</STRONG>

<B>Incidence of the residue at position 256&nbsp;on
the properties of HOE 140&nbsp;(<I>A</I>) and LF 16-0335&nbsp;(<I>B</I>).</B> The WT</A> or Phe<SUP>256</SUP>,
Gln<SUP>256</SUP>, or Ala<SUP>256</SUP> mutant B<SUB>2</SUB>
receptors were transiently expressed in COS-7 cells at similar levels
(6&nbsp;&#215;&nbsp;10<SUP>5</SUP>-10<SUP>6</SUP> sites/cell) and the ability
of the peptidic and nonpeptidic ligands to modulate IP</A> production
evaluated as indicated under "Experimental Procedures." The
presented typical experiment is representative of three separate
experiments. In these specific experiments designed for mutant
receptors and ligand comparisons, the basal WT</A> activity was not high
enough to evidence the inverse agonist activity of HOE 140&nbsp;and LF
16-0335,&nbsp;as previously observed (<A HREF="#B4">4</A>). The agonist efficacies of HOE 140&nbsp;for the Phe<SUP>256</SUP>, Gln<SUP>256</SUP>, and Ala<SUP>256</SUP>
receptors were 86,&nbsp;79,&nbsp;and 27% of the BK efficacies, respectively. The
efficacy of LF 16-0335&nbsp;for the Phe<SUP>256</SUP> mutant was 42% of
that of BK in the reported typical experiments. The
<I>K</I><SUB><I>d</I></SUB> values of <SUP>125</SUP>I-HPP-HOE 140&nbsp;and the
<I>K</I><SUB><I>i</I></SUB> values of LF 16-0335&nbsp;are collected in Table <a href="#TI">I</a>.
Similar results we found in three separate experiments and were also
obtained with LF 16-0687&nbsp;as nonpeptidic ligand.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 5 -->





<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF><NOBR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</NOBR><BR><NOBR><STRONG>View this table:</STRONG></NOBR>
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/TI">[in this window]</A></NOBR><BR>
<NOBR><A HREF="/cgi/content-nw/full/276/44/41100/TI"
	onClick="startTarget('TI', 500, 400); this.href='/cgi/content-nw/full/276/44/41100/TI'"
	onMouseOver="window.status='View table in a separate window';
		return true"
TARGET='TI'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="TI"><!-- TABLE I --></A>
<CENTER>
<B>Table I</B><BR>
<STRONG>

    Ligand recognition properties of human B<SUB><I>2</I></SUB> mutant receptors

<BR>
</STRONG>
</CENTER>
The affinities of [<SUP>3</SUP>H]BK and <SUP>125</SUP>I-HPP-HOE 140&nbsp;were
measured through direct binding experiments on membrane preparations
from COS-7 cells transiently expressing the WT</A> or mutant receptors.
Alternatively in some experiments [<SUP>3</SUP>H]BK binding was carried
out on intact cells; intact cells were not suitable for
<SUP>125</SUP>I-HPP-HOE 140&nbsp;binding because of passive ligand penetration,
which led to overestimated values. The expression levels for a given
plasmid amount (25-50 ng) was similar for the WT</A> and all mutant
receptors (1-3&nbsp;&#215;&nbsp;10<SUP>5</SUP> sites/cell), with the exception of
N198A and P258A, which displayed 10-fold reduced expression, and N297A,
which was not expressed at the plasma membrane but was intracellularly
detectable. The <I>K</I><SUB><I>i</I></SUB> values relative to the binding of
LF 16-0335 or LF 16-0687 were evaluated on membrane preparations, in
competition binding assays using <SUP>125</SUP>I-HPP-HOE 140&nbsp;as tracer
ligand. Each value is the mean&nbsp;&#177;&nbsp;S.D. of at least three separate
determinations.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>



    </P>
    

    
    <P>The essential role of Trp<SUP>256</SUP> was further supported by the
properties of receptors doubly mutated at positions 113&nbsp;and 256&nbsp;which<SUP> </SUP>were still constitutively activated: as previously described (<A HREF="#B4">4</A>),<SUP> </SUP>LF
16-0335&nbsp;displayed agonist properties on the N113A receptor<SUP> </SUP>which
possesses an extremely high constitutive activity. This<SUP> </SUP>agonist
property was only maintained for the N113A,W256F double<SUP> </SUP>mutant
(not shown). Therefore the residue at position 256&nbsp;modulates<SUP> </SUP>the
activation properties of a receptor which is strongly destabilized<SUP> </SUP>by
Asn<SUP>113</SUP> mutation to Ala. Taken together the data
indicate that Trp<SUP>256</SUP> controls in a subtle way the balance
between the stabilization<SUP> </SUP>of receptor inactive conformations and the
stabilization of intermediary<SUP> </SUP>or active conformations and that
Asn<SUP>113</SUP> and (or) Trp<SUP>256</SUP> possess other
interacting partners at some steps of the activation<SUP> </SUP>process.
    
    


    
    </P>

    


<P ALIGN=CENTER><B>Characterization of New Mutations Modulating Activation Properties:
Roles of Tyr<SUP>115</SUP> and Tyr<SUP>295</SUP></B>
</P>


    
    <P>The Pro<SUP>258</SUP> or Phe<SUP>252</SUP> mutations to
Ala did not induce any constitutive activation, so that the data
obtained upon mutation of these<SUP> </SUP>residues in TM</A> VI of other GPCR</A> (<A HREF="#B3">3</A>, <A HREF="#B20">20</A>)
cannot be generalized.<SUP> </SUP>The mutation of Gln<SUP>260</SUP> (TM</A> VI) to
His (B<SUB>1</SUB> homologous residue) did not change the basal<SUP> </SUP>activity; its mutation to Ala induced either a weak (2-fold) or<SUP> </SUP>no
constitutive activation according to experiments (Fig. <a href="#F3">3</a>).
    </P>
    

    
    <P>As Ser<SUP>111</SUP> was postulated to be involved in peptidic ligand
recognition specificity (<A HREF="#B21">21</A>), it was mutated to either Ala or Lys,<SUP> </SUP>its
B<SUB>1</SUB> counterpart. These mutations induced moderate but
significant<SUP> </SUP>losses of BK affinity. However, none of these mutations
induced<SUP> </SUP>any significant modification of basal IP</A> production<SUP> </SUP>activities.
    </P>
    

    
    <P>The most clearcut findings refer to the role of Tyr<SUP>115</SUP>,
located two residues below Asn<SUP>113</SUP> and homologous of the
rhodopsin Glu<SUP>122</SUP>. Important constitutive activations were
reproducibly elicited<SUP> </SUP>by Tyr<SUP>115</SUP> mutation: while its
mutation to Phe (the residue located at the<SUP> </SUP>homologous position in the
B<SUB>1</SUB> receptor) had no effect, its mutation<SUP> </SUP>to Ala
reproducibly induced a 5-fold increase in the basal IP</A><SUP> </SUP>production (Fig.
<a href="#F3">3</a>). The pharmacological properties of the nonpeptidic<SUP> </SUP>compound LF
16-0687&nbsp;for the Y115A receptor were unchanged as it<SUP> </SUP>behaved as in
inverse agonist, at variance with the CAM</A> N113A<SUP> </SUP>and W256F receptors.
Examination of the various models suggested<SUP> </SUP>some residues as possible
partners of Tyr<SUP>115</SUP>; a role for some of them was
experimentally ruled out: Ser<SUP>162</SUP>, Asn<SUP>202</SUP>, and
Phe<SUP>206</SUP> located in the vicinity of Gly<SUP>205</SUP>,
homologous of rhodopsin His<SUP>211</SUP> which was shown to interact
with Glu<SUP>122</SUP> (<A HREF="#B11">11</A>).
    </P>
    

    
    <P>The mutation of the conserved Asn<SUP>48</SUP> in TM</A> I did not induce
constitutive activation. These results differ from those reported<SUP> </SUP>for
the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>1B</SUB> and TRH receptors (<A HREF="#B22">22</A>, <A HREF="#B23">23</A>) and does not allow<SUP> </SUP>to
draw any conclusion about the connections between TMs I, II,<SUP> </SUP>and VII
(<A HREF="#B23">23-25</A>).
    </P>
    

    
    <P>We checked for possible interactions between Trp<SUP>256</SUP> and
residues of TM</A> V which are expected to face TM</A> VI. Phe<SUP>206</SUP>
mutation to Ala neither induced constitutive activation, nor<SUP> </SUP>significant modification of BK activation properties, leading<SUP> </SUP>to the
conclusion that the proposed interaction between the TM</A><SUP> </SUP>VI Trp and TM</A> V
Phe in the TRH receptor (<A HREF="#B26">26</A>) cannot be extrapolated.<SUP> </SUP>No significant
perturbation of activation properties could be<SUP> </SUP>detected for the D202A<SUP> </SUP>mutant.
    </P>
    

    
    <P>Tyr<SUP>295</SUP> mutation to Phe (<A HREF="#B4">4</A>) or to Ala in TM</A> VII of the
B<SUB>2</SUB> bradykinin receptor changed neither its basal IP</A>
production activity<SUP> </SUP>nor its BK activation properties (Fig. <a href="#F3">3</a> for basal
activities,<SUP> </SUP>data not shown for BK activation properties). These results
show<SUP> </SUP>that Tyr<SUP>295</SUP> does not play, by itself, a role similar
to that of the homologous<SUP> </SUP>Tyr<SUP>292</SUP> in the AT<SUB>1</SUB>
receptor. Nevertheless, as this residue, homologous<SUP> </SUP>of the rhodopsin
Lys<SUP>296</SUP>, was demonstrated to be an essential interaction
site with nonpeptidic<SUP> </SUP>compounds, together with Gln<SUP>288</SUP> (see
modeling section), we constructed some double mutants to<SUP> </SUP>check a
possible role of Tyr<SUP>295</SUP> in association with other residues.
Interestingly we found that<SUP> </SUP>while the Y295A and Q228A mutant displayed
moderately decreased<SUP> </SUP>recognition of BK and HOE140 (Table <a href="#TI">I</a>), the
Q228A,Y295A double<SUP> </SUP>mutant no longer recognized BK, and displayed
biphasic binding<SUP> </SUP>curves for <SUP>125</SUP>I-HPP-HOE 140&nbsp;with the
appearance of low affinity binding sites.<SUP> </SUP>Moreover the simultaneous Ala
mutation of Tyr<SUP>295</SUP>, Trp<SUP>256</SUP>, and
Phe<SUP>259</SUP> drastically affected the maximal BK stimulated IP</A>
production,<SUP> </SUP>which was not observed for the W256A,F259A double
mutant despite<SUP> </SUP>decreased BK potency (not shown). It indicated that
Tyr<SUP>295</SUP> plays some subtle role in receptor<SUP> </SUP>activation.
    </P>
    

    
    <P>Ala mutations of other TM</A> VII residues, Thr<SUP>287</SUP>,
Ser<SUP>291</SUP>, Ser<SUP>296</SUP>, and Ser<SUP>298</SUP>, did not
significantly alter the activation properties (Fig.<SUP> </SUP><a href="#F3">3</a>), while the
properties of the Asn<SUP>297</SUP> mutant could not be adequately
evaluated because of its poor<SUP> </SUP>expression. In this respect the behavior
of helix VII appeared<SUP> </SUP>significantly different in AT<SUB>1</SUB> and
B<SUB>2</SUB> receptors, as, in addition<SUP> </SUP>to Tyr<SUP>292</SUP>
mutation, mutations of Asn<SUP>294</SUP> and Asn<SUP>295</SUP> caused
inhibition of hormone-induced AT<SUB>1</SUB> receptor activation<SUP> </SUP>(<A HREF="#B27">27</A>).
    </P>
    

    



    


<P><I>On the Role of Phe<SUP>259</SUP> in the B<SUB>2</SUB> Receptor
Activation Mechanism--</I>

Phe<SUP>259</SUP>, located about one helix
turn above Trp<SUP>256</SUP>, is supposed to directly interact with
BK, together with Thr<SUP>263</SUP>; indeed we found dramatic losses
in BK affinity upon Phe<SUP>259</SUP> or (and) Thr<SUP>263</SUP>
mutations to Ala in the human B<SUB>2</SUB> receptor (Table <a href="#TI">I</a>),
consistent<SUP> </SUP>with previous findings for the rat receptor (<A HREF="#B19">19</A>). Therefore<SUP> </SUP>Phe<SUP>259</SUP> might be a "switch" residue playing a key role
in agonist-induced<SUP> </SUP>destabilization of inactive conformations. Previous
data on the<SUP> </SUP>AT<SUB>1</SUB> receptor have suggested that the transition
from inactive<SUP> </SUP>to active conformations might involve an interaction
between Trp<SUP>253</SUP> and His<SUP>256</SUP> (<A HREF="#B5">5</A>), the residues
homologous of the B<SUB>2</SUB> receptor Trp<SUP>256</SUP> and
Phe<SUP>259</SUP> respectively. It is noteworthy that
His<SUP>256</SUP> and Asn<SUP>111</SUP> were shown to interact with
the Phe<SUP>8</SUP> (<A HREF="#B16">16</A>, <A HREF="#B18">18</A>) and Tyr<SUP>4</SUP> (<A HREF="#B6">6</A>, <A HREF="#B13">13</A>) residues of
angiotensin II, respectively. There<SUP> </SUP>exists no evidence for or against
the possible interaction of<SUP> </SUP>Asn<SUP>113</SUP> with BK in the
B<SUB>2</SUB> receptor; the expected increase of agonist<SUP> </SUP>affinity for
CAM</A> receptors, recently observed for the B<SUB>1</SUB> receptor<SUP> </SUP>mutated at its conserved Asn residue (<A HREF="#B28">28</A>), was found neither<SUP> </SUP>for the
Ala<SUP>113</SUP> B<SUB>2</SUB> receptor (<A HREF="#B4">4</A>) nor for the N111A
AT<SUB>1</SUB> receptor (<A HREF="#B6">6</A>). It<SUP> </SUP>might result from compensatory effects
through the loss of BK-Asn<SUP>113</SUP> interaction. Answering this
question would imply an exhaustive<SUP> </SUP>structure-function analysis, as
performed for the AT<SUB>1</SUB> receptor<SUP> </SUP>using both receptor mutants
and hormone analogs (<A HREF="#B17">17</A>, <A HREF="#B18">18</A>).<SUP> </SUP>An alternative explanation is that
Asn<SUP>113</SUP> mutation mimicks a receptor perturbation induced by
BK through<SUP> </SUP>its interaction with Phe<SUP>259</SUP>. In this respect it
is tempting to postulate that there is some<SUP> </SUP>link between the roles of
Phe<SUP>259</SUP> and Asn<SUP>113</SUP>; indeed the lack of increase
in BK affinity upon Asn<SUP>113</SUP> to Ala mutation might reflect
some "redundancy" between the molecular<SUP> </SUP>events (and associated free
energy changes) triggered by BK-Phe<SUP>259</SUP> interaction and
Asn<SUP>113</SUP> mutation-induced facilitation of transition to
active conformations.<SUP> </SUP>It was corroborated by the fact that the
N113A,F259A (and also<SUP> </SUP>N113A,T263A) double mutant displayed
striking increases in BK<SUP> </SUP>affinity or potency for IP</A> production as
compared with the F259A<SUP> </SUP>single mutant (Table
<a href="#TII">II</a>), indicating that the
Asn<SUP>113</SUP> mutation is also able to favor some other molecular
events which<SUP> </SUP>are mediated by the Phe<SUP>259</SUP>-BK (and
Thr<SUP>263</SUP>-BK) interaction.

<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF><NOBR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</NOBR><BR><NOBR><STRONG>View this table:</STRONG></NOBR>
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/TII">[in this window]</A></NOBR><BR>
<NOBR><A HREF="/cgi/content-nw/full/276/44/41100/TII"
	onClick="startTarget('TII', 500, 400); this.href='/cgi/content-nw/full/276/44/41100/TII'"
	onMouseOver="window.status='View table in a separate window';
		return true"
TARGET='TII'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="TII"><!-- TABLE II --></A>
<CENTER>
<B>Table II</B><BR>
<STRONG>

    Binding and activation properties of B<SUB><I>2</I></SUB> receptors mutated at
positions 113,&nbsp;256,&nbsp;259&nbsp;and 263&nbsp;
<BR>
</STRONG>
</CENTER>
Direct binding of [<SUP>3</SUP>H]BK or <SUP>125</SUP>I-HPP-HOE140 and
competition binding of BK using this latter ligand as tracer were
carried out on membrane preparations from COS-7 cells transiently
expressing the WT</A> or mutant receptors. EC<SUB>50</SUB> values refer to
BK-induced IP</A> production in intact cells. The maximal stimulation
(<I>E</I><SUB>max</SUB>) were determined in the presence of
10<SUP><IMG SRC="/math/12pt/normal/scr/minus.gif" ALIGN=BOTTOM ALT="-">7</SUP> <font size=-1>M</font> BK. The values represent the mean&nbsp;&#177;&nbsp;S.D. of three separate experiments.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>



<P>
Other experimental findings are in favor of a concerted role of
Asn<SUP>113</SUP> and Phe<SUP>259</SUP>: the behavior of
B<SUB>2</SUB> receptors possessing either N113A and F259A<SUP> </SUP>mutations or
N113A and T263A mutations deserves a comment: the<SUP> </SUP>properties of these
double mutants revealed a discrepancy between<SUP> </SUP>the BK
<I>K</I><SUB><I>d</I></SUB> values determined by direct [<SUP>3</SUP>H]BK
binding (not possible in the single F259A and T263A mutants)<SUP> </SUP>and the
<I>K</I><SUB><I>i</I></SUB> values evaluated in competition binding assays<SUP> </SUP>using <SUP>125</SUP>I-HPP-HOE 140&nbsp;as tracer ligand (Table <a href="#TII">II</a>). It
might result from<SUP> </SUP>the existence of various conformational states,
displaying either<SUP> </SUP>high affinity for HOE 140&nbsp;and low affinity for BK
(preferentially<SUP> </SUP>binding the tracer ligand) or a high affinity for BK
(preferentially<SUP> </SUP>binding BK at low concentrations), together with a very
slow interconversion<SUP> </SUP>between these two states, as already described for
other receptors<SUP> </SUP>(<A HREF="#B29">29</A>). In the B<SUB>2</SUB> receptor context, the
observed discrepancies<SUP> </SUP>confirm that the mutations of residues 113&nbsp;and
259&nbsp;profoundly<SUP> </SUP>affect the pathways of conformational changes; the
additional<SUP> </SUP>mutation of Phe<SUP>259</SUP> (and therefore suppression of
BK-Phe<SUP>259</SUP> interaction) in the CAM</A> N113A receptor might in
some way limit<SUP> </SUP>the reversibility of specific steps in these<SUP> </SUP>pathways.
<P>
A concerted role for Phe<SUP>259</SUP> and Trp<SUP>256</SUP> could
also be inferred from the properties of receptors mutated at positions
256&nbsp;and 259.<SUP>&nbsp;</SUP>The CAM</A> W256F and W256Q receptors displayed no significant
increases<SUP> </SUP>in BK affinity. Phe<SUP>259</SUP> was also mutated to His,
its AT<SUB>1</SUB> counterpart. While the F259H<SUP> </SUP>receptor displayed
properties similar to those of the F259A mutant,<SUP> </SUP><I>i.e.</I>
strongly decreased affinity for BK (Table <a href="#TII">II</a>) and no constitutive<SUP> </SUP>activation, the F259H, W256F and F259H, W256Q receptors were
constitutively<SUP> </SUP>activated, similarly to the single Phe<SUP>256</SUP>
and Gln<SUP>256</SUP> mutants (not shown) and the EC<SUB>50</SUB> for
BK stimulation were dramatically<SUP> </SUP>decreased as compared with the W256H
receptor (these effects were<SUP> </SUP>much less pronounced for the F259H, W256A
receptor, which was<SUP> </SUP>not constitutively activated) (Table <a href="#TII">II</a>).
<P>
As a consequence our hypothesis is that the balance between active and
inactive conformations might be controlled by a network<SUP> </SUP>of concerted
interactions involving Asn<SUP>113</SUP>, Trp<SUP>256</SUP>, and
Phe<SUP>259</SUP> (Fig. <a href="#F8">8</a>) but obviously not restricted to these
residues. Besides<SUP> </SUP>its interaction with Trp<SUP>256</SUP>,
Asn<SUP>113</SUP> might interact with another residue located in
another TM</A> than<SUP> </SUP>TM</A> VI. By analogy to the AT<SUB>1</SUB> receptor,
Tyr<SUP>295</SUP> appeared as a plausible candidate, thus pointing to
coordinated<SUP> </SUP>roles of TMs III, VI, and VII. As detailed in Fig. <a href="#F8">8</a>, all
predictions<SUP> </SUP>about receptor interaction networks should take into
account the<SUP> </SUP>possible existence of a statistical distribution of
multiple conformational<SUP> </SUP>states each displaying only part of the
postulated<SUP> </SUP>interactions.



    


    


    
    </P>

    


<P ALIGN=CENTER><B>Docking of Nonpeptidic Ligands in a B<SUB>2</SUB> Receptor
Model</B>
</P>


    
    <P>Nonpeptidic ligands designed by Fournier Laboratories, inverse
agonists of the WT</A> receptor, are expected to stabilize or induce<SUP> </SUP>inactive receptor conformations. They might induce inactive
conformations<SUP> </SUP>characterized by a loss of
Asn<SUP>113</SUP>-Trp<SUP>256</SUP> interaction. However, the fact
that they become agonists of the<SUP> </SUP>Ala<SUP>113</SUP> CAM</A> receptor (<A HREF="#B4">4</A>)
which is no longer stabilized by this interaction,<SUP> </SUP>together with the
lack of experimental evidence for their interaction<SUP> </SUP>with
Asn<SUP>113</SUP>, suggest that the
Asn<SUP>113</SUP>-Trp<SUP>256</SUP> interaction is essentially
preserved in the nonpeptide-WT receptor<SUP> </SUP>complex. As a consequence,
nonpeptide ligands were docked into<SUP> </SUP>a receptor model built by homology
to the AT<SUB>1</SUB> receptor (<A HREF="#B13">13</A>),<SUP> </SUP>characterized by the
Asn<SUP>113</SUP>-Trp<SUP>256</SUP> and
Asn<SUP>113</SUP>-Tyr<SUP>295</SUP> proximities. Interestingly the
Asn<SUP>111</SUP>-Trp<SUP>253</SUP> interaction resulted from a
refinement of TM</A> VI position in initial<SUP> </SUP>models (<A HREF="#B5">5</A>), so as to allow the
double interaction of the tetrazole<SUP> </SUP>moiety of the nonpeptide losartan
with Lys<SUP>199</SUP> and His<SUP>256</SUP> (<A HREF="#B5">5</A>) (Fig.
<a href="#F6">6</a>). In parallel, we also performed a
docking of<SUP> </SUP>nonpeptidic ligands into a B<SUB>2</SUB> receptor model
homology-derived<SUP> </SUP>from the rhodopsin crystallographic structure (<A HREF="#B11">11</A>).
Three main<SUP> </SUP>candidates to nonpeptidic ligand recognition emerged from
the<SUP> </SUP>results collected in Table <a href="#TI">I</a>: Tyr<SUP>295</SUP>,
Gln<SUP>288</SUP>, and Trp<SUP>256</SUP>.



<BR CLEAR=ALL><A NAME="F6"><!-- FIG 6 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/44/41100/F6">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=147 HEIGHT=200 SRC="/content/vol276/issue44/images/small/bc4114724006.gif"></A><BR>

<STRONG>View larger version</STRONG> (47K):
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/F6">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/44/41100/F6"
onClick="startTarget('F6', 474, 640); this.href='/cgi/content-nw/full/276/44/41100/F6'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F6">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 6. &nbsp;</STRONG>

<B>Model of losartan interaction with the
AT<SUB>1</SUB> angiotensin II receptor.</B> Mutagenesis data
from our group or other groups (<A HREF="#B5">5</A>, <A HREF="#B16">16</A>) allowed the refinement of the
initial AT<SUB>1</SUB> receptor model (<A HREF="#B13">13</A>) so as to make possible the
double interaction of the losartan tetrazole moiety with
Lys<SUP>199</SUP> (TM</A> V) and His<SUP>256</SUP> (TM</A> VI) which is
important for receptor activation (<A HREF="#B5">5</A>, <A HREF="#B16">16</A>) and AII binding. Rotation of
TM</A> VI fulfilled this requirement, allowing Asn<SUP>111</SUP> to
interact with Trp<SUP>253</SUP>, in addition to its postulated
interaction with Tyr<SUP>292</SUP>. An essential interaction involves
the hydroxyl group of the ligand and the Asn<SUP>111</SUP> residue
(<A HREF="#B13">13</A>, <A HREF="#B17">17</A>, <A HREF="#B18">18</A>) which is essential for the stabilization of inactive
receptor conformations. <I>Top</I>, side view;
<I>bottom</I>, view from the extracellular side.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 6 -->




    </P>
    

    
    <P>The mutation of Tyr<SUP>295</SUP> to Phe or Ala induced moderate
perturbations of [<SUP>3</SUP>H]BK and <SUP>125</SUP>I-HPP-HOE 140&nbsp;binding (Table <a href="#TI">I</a>). Tyr<SUP>295</SUP> appeared to be essential for
nonpeptide affinity; its mutation<SUP> </SUP>to Phe and Ala induced a gradual
increase in <I>K</I><SUB><I>i</I></SUB> values<SUP> </SUP>for LF 16-0687&nbsp;(8-10-fold and
130-140-fold increases, respectively).<SUP> </SUP>Interestingly the loss of
affinity upon Tyr to Phe mutation was<SUP> </SUP>significantly attenuated,
irrespective of the tracer ligand used,<SUP> </SUP>for the compound LF 18-1300&nbsp;which possesses an imidazole moiety<SUP> </SUP>at position 4&nbsp;of the quinoline
(Table <a href="#TIII">III</a>). The interpretation<SUP> </SUP>is
that Tyr<SUP>295</SUP> interacts with the quinoline and that the loss
of hydroxyl group<SUP> </SUP>upon its mutation to Phe is compensated by the
presence of the<SUP> </SUP>imidazole in LF 18-1300.&nbsp;The similar affinity losses
upon Tyr<SUP> </SUP>mutation for LF 18-1300&nbsp;and LF 18-1833,&nbsp;a related compound
lacking<SUP> </SUP>the benzamidine moiety at its extremity, precludes a Tyr
interaction<SUP> </SUP>with the benzamidine, which significantly contributes to
the affinity<SUP> </SUP>of LF 16-0335,&nbsp;LF 16-0687,&nbsp;and LF 18-1300.&nbsp;The
Tyr-quinoline interaction<SUP> </SUP>is consistent with the essential role of
quinoline emerging from<SUP> </SUP>the chemical design of LF 16-0687&nbsp;and the
dramatic loss of affinity<SUP> </SUP>induced by Ala mutation of
Tyr<SUP>295</SUP>.

<P><CENTER>
<TABLE BORDER WIDTH="95%" CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1><TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF><NOBR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</NOBR><BR><NOBR><STRONG>View this table:</STRONG></NOBR>
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/TIII">[in this window]</A></NOBR><BR>
<NOBR><A HREF="/cgi/content-nw/full/276/44/41100/TIII"
	onClick="startTarget('TIII', 500, 400); this.href='/cgi/content-nw/full/276/44/41100/TIII'"
	onMouseOver="window.status='View table in a separate window';
		return true"
TARGET='TIII'>[in a new window]</A><BR>&nbsp;</NOBR>
</TD>
<TD ALIGN=LEFT VALIGN=TOP>
<A NAME="TIII"><!-- TABLE III --></A>
<CENTER>
<B>Table III</B><BR>
<STRONG>

    Binding properties of the various nonpeptidic ligands to the WT</A> or
mutant B<SUB><I>2</I></SUB> receptors

<BR>
</STRONG>
</CENTER>
The properties of the WT</A> or mutant receptors were determined as
described under "Experimental Procedures." The chemical structures
of the nonpeptidic ligands are precised in Fig. <a href="#F2">2</a>. The values represent
the mean of at least three separate experiments.

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>



    </P>
    

    
    <P>Significant losses in nonpeptide affinity were observed for the W256A
mutant (Fig. <a href="#F5">5</a>, Table <a href="#TI">I</a>, Table <a href="#TII">II</a>); their relatively<SUP> </SUP>moderate
intensities can be interpreted as resulting from compensatory<SUP> </SUP>effects
involving the reinforcement of Tyr<SUP>295</SUP>-quinoline interaction
in the mutant receptor. The decreases in<SUP> </SUP>nonpeptide affinity were lower
for the W256F and W256Q mutants<SUP> </SUP>which were constitutively activated and
therefore displayed modified<SUP> </SUP>conformational equilibria with increased
representations of active<SUP> </SUP>conformations. The changes in the
pharmacological properties of<SUP> </SUP>the nonpeptide for the various mutants
support the hypothesis<SUP> </SUP>of nonpeptide-Trp<SUP>256</SUP> interaction: as
LF 16-0335,&nbsp;LF 16-0687,&nbsp;LF 18-1300,&nbsp;and LF 18-1833<SUP>&nbsp;</SUP>became agonists of
the W256F receptor, but not of the W256Q receptor,<SUP> </SUP>we postulated that
an aromatic-aromatic interaction between the<SUP> </SUP>W256F receptor and the
ligand was responsible for the agonist<SUP> </SUP>action of this latter; as
detailed in the recapitulative scheme<SUP> </SUP>(Fig. <a href="#F8">8</a>) the ligand conformation
interacting with the W256F CAM</A><SUP> </SUP>receptor should be different from that
interacting with the inactive<SUP> </SUP>conformation of the WT</A><SUP> </SUP>receptor.
    </P>
    

    
    <P>As a consequence we postulated the existence of a sandwich packing
comprising Tyr<SUP>295</SUP>-quinoline-Trp<SUP>256</SUP>. The drastic
loss of nonpeptide affinity for the W256A,Y295A<SUP> </SUP>double mutant
(Table <a href="#TIII">III</a>) supports this hypothesis. The alternative<SUP> </SUP>hypothesis of
Tyr<SUP>295</SUP> and Trp<SUP>256</SUP> separate interactions with
the quinoline and dichlorophenyl ligand<SUP> </SUP>groups, respectively, appeared
impossible to be fulfilled, because<SUP> </SUP>of the steric hindrance of the
dichlorophenyl group and the importance<SUP> </SUP>of its link to the
SO<SUB>2</SUB>-prolyl portion in the ligand conformation.<SUP> </SUP>The
hypothesis of Trp<SUP>256</SUP> interaction with the benzamidine
moiety of LF 16-0687&nbsp;and LF<SUP> </SUP>18-1300&nbsp;was also excluded because of the
similar behavior of LF<SUP> </SUP>18-1833.
    </P>
    

    
    <P>All nonpeptidic ligands displayed ~10-fold decreased affinities for
the Q288A mutant, as compared with the WT</A> receptor (Table<SUP> </SUP><a href="#TIII">III</a>).
Here again the behavior of the "shortened" compound LF 18-1833<SUP>&nbsp;</SUP>could not be distinguished from that of compounds possessing the<SUP> </SUP>benzamidine. As expected, the simultaneous mutation of
Tyr<SUP>295</SUP> and Gln<SUP>288</SUP> elicited drastic losses in
nonpeptide affinity (<I>K</I><SUB><I>i</I></SUB> value<SUP> </SUP>difficult to evaluate
because of multiple sites for the tracer<SUP> </SUP>ligand
<SUP>125</SUP>I-HPP-HOE<SUP> </SUP>140).
    </P>
    

    
    <P>These experimental results constituted the support for the docking of
nonpeptide ligands into a model of receptor inactive<SUP> </SUP>conformation,
derived from previous AT<SUB>1</SUB> and B<SUB>2</SUB> receptor
studies<SUP> </SUP>(<A HREF="#B4">4-6</A>, <A HREF="#B15">15</A>). The docking strategy (see details under
"Experimental<SUP> </SUP>Procedures") positioned the benzamidine moiety of LF
16-0687&nbsp;at<SUP> </SUP>the extracellular space boundary of the transmembrane helix
bundle.<SUP> </SUP>Further experimentation would be required to detect receptor
residues<SUP> </SUP>responsible for its interaction with benzamidine which is not<SUP> </SUP>an absolutely required pharmacophore but nevertheless improves<SUP> </SUP>ligand
affinity. The possible candidates to an interaction with<SUP> </SUP>the
benzamidine appeared to be Asp<SUP>266</SUP>, Thr<SUP>267</SUP>,
Asp<SUP>279</SUP>, Glu<SUP>280</SUP>, and Asp<SUP>284</SUP>; this
latter residue was excluded on the basis of D284A mutant<SUP> </SUP>properties.
    </P>
    

    
    <P>The model of the minimized LF 16-0687-receptor complex, termed as
experimental model, is represented in Fig.
<a href="#F7">7</a><I>A</I>. This minimization<SUP> </SUP>did not
significantly change the position of TM</A> VII which was<SUP> </SUP>kept free of
constraints together with the adjacent loops. An<SUP> </SUP>opened question is the
participation of Asn<SUP>113</SUP> to ligand interaction, through
hydrogen bonding to the oxygen<SUP> </SUP>atom directly linked to the quinoline.
The lack of incidence of<SUP> </SUP>Asn<SUP>113</SUP> to Ala mutation on LF
16-0687&nbsp;affinity is not necessarily inconsistent<SUP> </SUP>with this possibility
as the mutation drastically shifts conformational<SUP> </SUP>equilibria to active
states, conferring agonist properties to<SUP> </SUP>the nonpeptidic ligand. As
above indicated, optimization of the<SUP> </SUP>geometry of the microdomain
constituted by Asn<SUP>113</SUP>, Trp<SUP>256</SUP>, and
Tyr<SUP>295</SUP> and the ligand quinoline, which might not be unique
(and its<SUP> </SUP>relationship with the Asn<SUP>113</SUP>-Trp<SUP>256</SUP>
interaction) is not easily feasible through use of semi-empirical<SUP> </SUP>quantum mechanics calculations, taking into account the difficulty<SUP> </SUP>to
assess the relevance of expectedly weak differences in energy<SUP> </SUP>levels of
conformations corresponding to different possibilities<SUP> </SUP>of packing the
involved chemical structures.



<BR CLEAR=ALL><A NAME="F7"><!-- FIG 7 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/44/41100/F7">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=200 HEIGHT=140 SRC="/content/vol276/issue44/images/small/bc4114724007.gif"></A><BR>

<STRONG>View larger version</STRONG> (56K):
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/F7">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/44/41100/F7"
onClick="startTarget('F7', 590, 508); this.href='/cgi/content-nw/full/276/44/41100/F7'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F7">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 7. &nbsp;</STRONG>

<B>Models of the human B<SUB>2</SUB> receptor
interaction with the nonpeptidic compound LF 16-0687.</B>&nbsp;The model
represented in <I>A</I> was homology-derived from the
AT<SUB>1</SUB> model as described under "Experimental Procedures,"
with a slight modification of TM</A> VII position. The represented inactive
receptor conformation is stabilized by a
Asn<SUP>113</SUP>-Trp<SUP>256</SUP> interaction, which received
experimental support. The nonpeptidic compound binding to the receptor
involves interaction of the ligand quinoline moiety with
Tyr<SUP>295</SUP> and Trp<SUP>256</SUP> and interaction of the
carbonyl function of the prolyl moiety with Gln<SUP>288</SUP>.
Interestingly receptor residues involved in nonpeptide binding are
located at strategic positions, important for the control of
conformational equilibria in the B<SUB>2</SUB> receptor itself or
other GPCR</A>, including rhodopsin and the AT<SUB>1</SUB> receptor. The
model represented in <I>B</I> was homology-derived from the
rhodopsin structure. The nonpeptidic ligand docking can be achieved
using the same ligand-receptor contact points as in <I>A</I>; the
bent form of the ligand extremity bearing the benzamidine moiety
results from the arbitrary transposition to the B<SUB>2</SUB> receptor
of the lid role of some rhodopsin extracellular loops (<A HREF="#B11">11</A>).
<I>Top</I>, side view; <I>bottom</I>, view from the
extracellular side.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 7 -->




    </P>
    

    
    <P>Preliminary positioning of LF 18-1300&nbsp;into B<SUB>2</SUB> receptor
models made no interaction of additional receptor residues with its<SUP> </SUP>imidazole moiety, suggesting that this latter probably induces<SUP> </SUP>a
reinforcement of the quinoline interaction with its partners<SUP> </SUP>Tyr<SUP>295</SUP> and (or) Trp<SUP>256</SUP>. Here again the success
of theoretical calculations is not guaranteed.<SUP> </SUP>As previously mentioned
it is noteworthy that a model of losartan-AT<SUB>1</SUB><SUP> </SUP>receptor
interaction (Fig. <a href="#F6">6</a>), consistent with abundant experimental<SUP> </SUP>structure-function and activation data, was based on similar hypotheses<SUP> </SUP>of inactive receptor conformation (<A HREF="#B5">5</A>, <A HREF="#B13">13</A>), including the<SUP> </SUP>essential
stabilizing Asn<SUP>111</SUP>-Trp<SUP>253 </SUP>interaction.
    </P>
    

    
    <P>A B<SUB>2</SUB> receptor model, homology-derived from the
crystallographic data of rhodopsin (termed as rhodopsin-like model),
was also<SUP> </SUP>built (Fig. <a href="#F7">7</a><I>B</I>). The flexibility of the ligand LF
16-0687&nbsp;made<SUP> </SUP>possible a docking into this model which satisfied the
same interactions<SUP> </SUP>as in the preceding model, including a sandwich
position of the<SUP> </SUP>ligand quinoline with Tyr<SUP>295</SUP> and
Trp<SUP>256</SUP> which is postulated to be essential for the
stabilization of<SUP> </SUP>inactive receptor conformations. In this model, the
ligand extremity<SUP> </SUP>bearing the benzamidine moiety adopts a more bent
shape, so as<SUP> </SUP>to keep conserved possible constraints of extracellular
loops<SUP> </SUP>which, in the rhodopsin structure, function as a lid preventing<SUP> </SUP>retinal from going out of the binding pocket. In the absence of<SUP> </SUP>any
data about residues interacting with the benzamidine, it is<SUP> </SUP>difficult
to support any hypothesis about the position of this<SUP> </SUP>ligand extremity
as well as the role of the B<SUB>2</SUB> receptor extracellular<SUP> </SUP>loops
in the delimitation of the binding<SUP> </SUP>site.
    </P>
    

    
    <P>The comparison of the experimental and rhodopsin-like models was
focused on residues which display interesting activation<SUP> </SUP>and ligand
recognition properties, more particularly on Asn<SUP>113</SUP>,
Trp<SUP>256</SUP>, and Tyr<SUP>295</SUP> which are essential for the
relative positioning of TMs III,<SUP> </SUP>VI, and VII and therefore the
positions of other residues located<SUP> </SUP>on them (Tyr<SUP>115</SUP>,
Phe<SUP>259</SUP>, Gln<SUP>260</SUP>, and Gln<SUP>288</SUP>). It is
noteworthy that the proximity between Asn<SUP>113</SUP> and
Trp<SUP>256</SUP>, which constitutes an essential hypothesis of the
present work,<SUP> </SUP>is more consistent with the rhodopsin structure than with
previous<SUP> </SUP>rhodopsin models (<A HREF="#B9">9</A>, <A HREF="#B10">10</A>). Indeed the distance between the<SUP> </SUP><IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha ">&nbsp;carbon atoms of Gly<SUP>120</SUP> and Trp<SUP>265</SUP>, the
rhodopsin residues homologs of the B<SUB>2</SUB> Asn<SUP>113</SUP>
and Trp<SUP>256</SUP> is 11.5&nbsp;&Aring;&nbsp;in the crystallographic
structure while it is strikingly<SUP> </SUP>higher in the model by Herzyk <I>et
al.</I> (<A HREF="#B10">10</A>) (15.1&nbsp;&Aring;); the corresponding<SUP> </SUP>distance in our
experimental AT<SUB>1</SUB> and B<SUB>2</SUB> receptor models is 9.5<SUP>&nbsp;</SUP>&Aring;&nbsp;and the spatial arrangement of helices III and VI allows hydrogen<SUP> </SUP>bond or amino-aromatic interactions between the side chains, in<SUP> </SUP>a
B<SUB>2</SUB> receptor model built by homology to the rhodopsin
structure,<SUP> </SUP>the distance between the Asn<SUP>113</SUP> and
Trp<SUP>256</SUP> side chains is not compatible with the geometrical
possibility<SUP> </SUP>of an hydrogen bond interaction, because of a 40&#176;
difference in<SUP> </SUP>the orientation of TM</A> III, but the addition of a water
molecule<SUP> </SUP>between the two side chains would account for their functional<SUP> </SUP>interaction. The ability of Zn<SUP>2+</SUP> ions to coordinate
histidine residues simultaneously introduced<SUP> </SUP>at these positions is an
essential verification of the proximity<SUP> </SUP>between Asn<SUP>113</SUP> and
Trp<SUP>256</SUP>. A careful analysis of models possessing the
histidine mutations<SUP> </SUP>at these positions revealed that Zn<SUP>2+</SUP>
ion coordination is theoretically possible in our experimental<SUP> </SUP>B<SUB>2</SUB> receptor model as well as in the rhodopsin-like model
(minimal<SUP> </SUP>distances between the <IMG SRC="/math/12pt/normal/delta.gif" ALIGN=BOTTOM ALT="delta ">-N histidine atoms 5.3&nbsp;and 5.3&nbsp;&Aring;,
respectively,<SUP> </SUP>corresponding distances between the <IMG SRC="/math/12pt/normal/epsilon.gif" ALIGN=BOTTOM ALT="epsilon ">-N histidine atoms
2.0&nbsp;and<SUP> </SUP>5.4&nbsp;&Aring;, respectively). Further comparisons revealed that the
Asn<SUP>111</SUP>-Tyr<SUP>292</SUP> or
Asn<SUP>113</SUP>-Tyr<SUP>295</SUP> proximity in the experimental
AT<SUB>1</SUB> or B<SUB>2</SUB> receptor models is consistent<SUP> </SUP>with
the Herzyk's rhodopsin models (<A HREF="#B10">10</A>) while it does not exactly<SUP> </SUP>match the
rhodopsin-like model (difference in the distances between<SUP> </SUP>side chains
less than 2&nbsp;&Aring;&nbsp;in terms of hydrogen bonding possibility).<SUP> </SUP>At the
present stage of these studies it is difficult to privilege<SUP> </SUP>one of the
two proposed models or to exclude that an intermediary<SUP> </SUP>model would be
more<SUP> </SUP>realistic.
    
    


    
    </P>

    


<P ALIGN=CENTER><B>Summarized Picture of Interaction Networks Controlling
B<SUB>2</SUB> Receptor Conformational Equilibria and Their Modulation
by Mutations or Ligand Action</B>
</P>


    
    <P>Fig. <a href="#F8">8</a> represents tentative
explanations for a wide set of pharmacological data relative to ligand
recognition and activation<SUP> </SUP>or inactivation properties of the human
B<SUB>2</SUB> bradykinin receptor,<SUP> </SUP>with special attention to the key
or switch roles of residues<SUP> </SUP>involved in the control of conformational
equilibria or the binding<SUP> </SUP>of nonpeptidic ligands, or both.



<BR CLEAR=ALL><A NAME="F8"><!-- FIG 8 --></A>

<P><CENTER><TABLE BORDER WIDTH=95% CELLPADDING=0 CELLSPACING=0><TR BGCOLOR=E1E1E1><TD>
<TABLE CELLPADDING=2 CELLSPACING=2><TR BGCOLOR=E1E1E1>
<TD ALIGN=CENTER VALIGN=TOP BGCOLOR=FFFFFF>

<A HREF="/cgi/content/full/276/44/41100/F8">
<IMG HSPACE=10 VSPACE=5 BORDER=2 WIDTH=200 HEIGHT=132 SRC="/content/vol276/issue44/images/small/bc4114724008.gif"></A><BR>

<STRONG>View larger version</STRONG> (33K):
<BR><NOBR><A HREF="/cgi/content/full/276/44/41100/F8">[in this window]</A>
<BR><A HREF="/cgi/content-nw/full/276/44/41100/F8"
onClick="startTarget('F8', 590, 491); this.href='/cgi/content-nw/full/276/44/41100/F8'"
    onMouseOver="window.status='View figure in a separate window'; return true"
    TARGET="F8">[in a new window]</A><BR>&nbsp;
</NOBR>
</TD><TD ALIGN=LEFT VALIGN=TOP>

<STRONG>Fig. 8. &nbsp;</STRONG>

<B>Elements of networks stabilizing
B<SUB>2</SUB> receptor inactive conformations and mechanisms of their
mutation or ligand-induced perturbations.</B> Likely or possible
interactions stabilizing inactive receptor conformations are indicated
by <I>dashed lines</I>; the sluices drawn on these <I>dashed
lines</I> materialize a statistical distribution of various
conformational states in which the interactions might not be fulfilled
simultaneously. The ability of BK or receptor mutations to increase IP</A>
production through interaction networks destabilization is materialized
by the number of&nbsp;+&nbsp;symbols. The central core of networks stabilizing
inactive conformations is postulated to be constituted by the
Asn<SUP>113</SUP>-Trp<SUP>256</SUP>-Phe<SUP>259</SUP> triad, taking
into account the Asn<SUP>113</SUP>-Trp<SUP>256</SUP> proximity and
the role of Phe<SUP>259</SUP> in BK binding. The other residues which
are probably connected in direct or indirect ways to this triad are
Asp<SUP>76</SUP>, Gln<SUP>260</SUP>, Gln<SUP>288</SUP>, and
Tyr<SUP>295</SUP>. The basal activity of the WT</A> receptor would be
accounted for by the existence of transition or activated states such
as state 2,&nbsp;characterized by an intrahelical interaction inside TM</A> VI
and the loss of TM</A> III-TM VI contacts, and ultimate states materialized
as 3,4,&nbsp;... ,&nbsp;which might display modifications of TM</A> III, VI, and
VII (and probably other TMs) positioning. BK contact with
Phe<SUP>259</SUP> would greatly contribute to the destabilization of
inactive conformations; therefore Phe<SUP>259</SUP> would act as a
switch residue, and for instance, might favor the transition to
conformations such as 2.&nbsp;The strikingly high constitutive activation
induced by Asn<SUP>113</SUP> to Ala mutation would result from the
complete loss of TM</A> III-TM VI and TM</A> III-TM VII interactions. It is
conceivable that, because of this strong destabilization, the
conformational change pathways and resulting activated states are
different from those followed by the WT</A> receptor; it is likely that BK
activates the WT</A> receptor through more coordinated and more readily
reversible conformational changes leading to the loss of specific
helix-helix interactions. The constitutive activation of the
Phe<SUP>256</SUP> or Gln<SUP>256</SUP> mutants would result from a
perturbation of TM</A> III-TM VI contacts, with under-representation of
inactive conformations and over-representation of conformations 2.&nbsp;The
lack of constitutive activation of the Ala<SUP>256</SUP> mutant or the
Ala<SUP>259</SUP> mutant would result from compensation of lost
interactions by over-representation of conformations possessing, for
instance, Asn<SUP>113</SUP>-Tyr<SUP>295</SUP> and
Asn<SUP>113</SUP>-Trp<SUP>256</SUP> interactions, respectively. The
lack of constitutive activation of the W256A,F259A double mutant
might result from the preservation or reinforcement of the
Asn<SUP>113</SUP>-Tyr<SUP>295</SUP> interaction. An interesting
question is the role of Tyr<SUP>115</SUP>, homologous of the rhodopsin
Glu<SUP>122</SUP>, in stabilizing inactive conformations. The precise
roles of Tyr<SUP>115</SUP>, Phe<SUP>259</SUP>, Gln<SUP>260</SUP>,
Tyr<SUP>295</SUP>, and Gln<SUP>288</SUP> in intra- or inter-helical
stabilizations require further experimentation. Tyr<SUP>295</SUP>,
Trp<SUP>256</SUP>, and Gln<SUP>288</SUP> are likely candidates for
the binding of the nonpeptidic ligand LF 16-0687,&nbsp;the ligand quinoline
pharmacophore occupying a sandwich position between Tyr<SUP>295</SUP>
and Trp<SUP>256</SUP>. The changes in the pharmacological properties
of this nonpeptidic ligand which became agonist of the CAM</A> N113A and
W256F receptors led us to postulate that the most representative
conformations of the ligand receptor complexes might display the
following properties: the ligand-WT receptor complex should be
stabilized by the Asn<SUP>113</SUP>-Trp<SUP>256</SUP> interaction
(conformations 5), possibly reinforced by a role of the ligand in
maintaining the Trp in the adequate position; these ligand-receptor
interactions would contribute to restrain the relative motions of TMs
III, VI, and VII. In the N113A and W256F receptors, which are
constitutively activated and overactivated by the nonpeptidic ligand,
the major conformations representative of the agonist ligand-CAM
receptor complexes would no longer possess connections between
Asn<SUP>113</SUP> and Trp<SUP>256</SUP>; the favored motions of TM</A>
III, VI, and VII would result in the preferential stabilization of
complexes symbolized by 6&nbsp;and 7&nbsp;which are expected to be structurally
different of 5; this preferential stabilization (or induction) of
active conformations of the CAM</A> receptors would be facilitated by the
nonpeptidic ligand flexibility allowing this conformational
adaptation.


<BR CLEAR=LEFT>

</TD></TR></TABLE>
</TD></TR></TABLE>
</CENTER>
<!-- /FIG 8 -->




    
    


    
    


<BR><BR CLEAR=ALL>


<A NAME="SEC3"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;DISCUSSION</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">RESULTS</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>DISCUSSION</FONT>


<BR>
<A HREF="#References"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/darrow.gif">REFERENCES</A>
</FONT></TH>
</TR></TABLE>


    
    <P>The human B<SUB>2</SUB> bradykinin receptor possesses an extreme
conformational flexibility, and thus constitutes a model of choice to<SUP> </SUP>investigate the control of conformational equilibria by ligands.<SUP> </SUP>Consistently with modeling studies of the AT<SUB>1</SUB> receptor
which originated<SUP> </SUP>these studies we hypothesized that an interaction
between Asn<SUP>113</SUP> and Trp<SUP>256</SUP> could play a major
role on the stabilization of an inactive B<SUB>2</SUB><SUP> </SUP>receptor
conformation (<A HREF="#B4">4</A>). A first essential finding of the<SUP> </SUP>work was the
biochemical evidence for the proximity between these<SUP> </SUP>two residues,
provided by the ability of Zn<SUP>2+</SUP> ions to coordinate
histidine residues simultaneously introduced<SUP> </SUP>at these positions. It is
noteworthy that this proximity is in<SUP> </SUP>better agreement with the recently
determined rhodopsin structure<SUP> </SUP>(<A HREF="#B11">11</A>) than previously published rhodopsin
models (<A HREF="#B9">9</A>, <A HREF="#B10">10</A>,<SUP> </SUP><A HREF="#B31">31</A>).
    
    </P>

    
    <P>Extensive investigations were devoted to the function of
Trp<SUP>256</SUP>, fairly conserved in many GPCR</A>. A detailed
pharmacological study<SUP> </SUP>of the various mutants, including nonpeptide
ligand recognition<SUP> </SUP>and activation properties, led to the conclusion
that the residue<SUP> </SUP>at position 256&nbsp;exerts a subtle control of the balance
between<SUP> </SUP>inactive and active receptor conformations. The importance of<SUP> </SUP>this tryptophan in GPCR</A> function is underlined by initial photolabeling<SUP> </SUP>experiments demonstrating that the homologous Trp<SUP>265</SUP> in
rhodopsin lies in the retinal binding pocket (<A HREF="#B32">32</A>); it was<SUP> </SUP>confirmed by
crystallographic data (<A HREF="#B11">11</A>) and a more detailed<SUP> </SUP>study of rhodopsin
conformational changes associated to retinal<SUP> </SUP>photoisomerization
suggested that Trp<SUP>265</SUP> keeps 11-<I>cis-</I>retinal as an
inverse agonist (<A HREF="#B33">33</A>). The same tryptophan<SUP> </SUP>was shown to participate in
the stabilization of a inactive TRH<SUP> </SUP>receptor conformation (<A HREF="#B26">26</A>), through
interaction with TM</A> V, a<SUP> </SUP>finding that could not be extrapolated to the
B<SUB>2</SUB><SUP> </SUP>receptor.
    
    </P>

    
    <P>The search for partners interacting with Asn<SUP>113</SUP> or
Trp<SUP>256</SUP> led us to address the possible role of
Phe<SUP>259</SUP>, which is a BK interaction site and is located one
helix turn<SUP> </SUP>above Trp<SUP>256</SUP> in TM</A> VI and Tyr<SUP>295</SUP>,
which is adequately located for a possible interaction with<SUP> </SUP>Asn<SUP>113</SUP> and might play a role in the transition to activated
states,<SUP> </SUP>in association with other key residues. The inactivation of the<SUP> </SUP>AT<SUB>1</SUB> receptor (<A HREF="#B15">15</A>) and the constitutive activation of the
<IMG SRC="/math/12pt/normal/delta.gif" ALIGN=BOTTOM ALT="delta ">-opioid<SUP> </SUP>receptor (<A HREF="#B34">34</A>) observed when the homologous Tyr residues were<SUP> </SUP>mutated probably reflect some conserved features with rhodopsin<SUP> </SUP>which
covalently binds retinal by its Lys<SUP>296</SUP> located at the same<SUP> </SUP>position.
    
    </P>

    
    <P>The search for additional residues which might participate in the
stabilization of inactive B<SUB>2</SUB> receptor conformations led<SUP> </SUP>us
to evidence strong constitutive activation upon Ala mutation<SUP> </SUP>of
Tyr<SUP>115</SUP>. Tyr<SUP>115</SUP>, located about half an helix
turn below Asn<SUP>113</SUP> in TM</A> III, is homologous of
Glu<SUP>122</SUP><SUB>,</SUB> which is important for rhodopsin
function<SUP> </SUP>(<A HREF="#B35">35</A>) and interacts with His<SUP>211</SUP> in the inactive
crystal form (<A HREF="#B11">11</A>, <A HREF="#B36">36</A>).
    
    </P>

    
    <P>We constructed a B<SUB>2</SUB> receptor model inherited of previous
building (<A HREF="#B13">13</A>) and refinements (<A HREF="#B5">5</A>) of an AT<SUB>1</SUB> receptor model,<SUP> </SUP>and based on the Asn<SUP>113</SUP> proximity to Trp<SUP>256</SUP> and
Tyr<SUP>295</SUP>. Interestingly these proximities can be considered
as in fairly<SUP> </SUP>good agreement with rhodopsin crystallographic structure
(<A HREF="#B11">11</A>).<SUP> </SUP>At this stage the question is raised to which extent it is
justified<SUP> </SUP>to deduce the various GPCR</A> models from the structure of
rhodopsin.<SUP> </SUP>A first consideration is the possible participation of water
molecules<SUP> </SUP>in hydrogen bond networks which is liable to modify distances<SUP> </SUP>between residues which are supposed to interact on the basis of<SUP> </SUP>experimental results. The bacteriorhodopsin and rhodopsin examples<SUP> </SUP>demonstrate the importance of water molecules and their redistribution<SUP> </SUP>associated to retinal photoisomerization (<A HREF="#B37">37</A>, <A HREF="#B38">38</A>). Another<SUP> </SUP>consideration is that the inactive rhodopsin conformation is covalently<SUP> </SUP>linked to retinal which behaves as an inverse agonist in the absence<SUP> </SUP>of
light and should contribute to induce a specific conformation<SUP> </SUP>which
cannot be transposed to other liganded or unliganded GPCR</A>.<SUP> </SUP>Indeed the
role of either all-<I>trans</I>-retinal in bacteriorhodopsin<SUP> </SUP>or
11-<I>cis</I>-retinal in rhodopsin in exerting constraints on
transmembrane<SUP> </SUP>helices has been well documented and retinal
isomerization has<SUP> </SUP>been shown to induce significant changes in the helix
bundle organization<SUP> </SUP>(<A HREF="#B33">33</A>, <A HREF="#B39">39-45</A>). An elegant recent study demonstrates
that appropriate<SUP> </SUP>rhodopsin illumination drastically changes the site of
its covalent<SUP> </SUP>labeling by photoactivatable retinal derivatives and that
the<SUP> </SUP>generation of some photointermediates is accompanied by helix<SUP> </SUP>motions (<A HREF="#B33">33</A>).
    
    </P>

    
    <P>The postulated interaction network is consistent with the importance of
TMs III, VI, and VII motions for GPCR</A> activation (<A HREF="#B1">1</A>,<SUP> </SUP><A HREF="#B46">46</A>); it would
provide a plausible explanation to the destabilizing<SUP> </SUP>action of BK
through direct interaction with Phe<SUP>259</SUP>. It is noteworthy
that similar considerations can be put forward<SUP> </SUP>for AII interaction with
Asn<SUP>111</SUP> and His<SUP>256</SUP> in the AT<SUB>1</SUB>
receptor (<A HREF="#B5">5</A>, <A HREF="#B16">16</A>). It is necessary to emphasize<SUP> </SUP>that conformational
states simultaneously displaying all the possible<SUP> </SUP>interactions inside
these networks might have no physical reality<SUP> </SUP>but the "inactive
conformation" might cover a set of conformational<SUP> </SUP>states each
displaying only part of these interactions. The consequence<SUP> </SUP>of
mutations or ligand binding would be a change in the statistical<SUP> </SUP>distribution of the conformational states or the induction of<SUP> </SUP>new<SUP> </SUP>states.
    
    </P>

    
    <P>Although the characterization of GPCR</A> activated states is not presently
available, with the exception of punctual information<SUP> </SUP>(<A HREF="#B47">47</A>, <A HREF="#B48">48</A>), the
Asn<SUP>113</SUP>-Trp<SUP>256</SUP> and
Trp<SUP>256</SUP>-Phe<SUP>259</SUP> spatial proximities in the
B<SUB>2</SUB> receptor are consistent with specific<SUP> </SUP>local
rearrangements which can be predicted to take place during<SUP> </SUP>activation.
Based on the previous hypothesis of
Trp<SUP>253</SUP>-His<SUP>256</SUP> interaction in the
AT<SUB>1</SUB> receptor activation process (<A HREF="#B5">5</A>), and<SUP> </SUP>the properties of
B<SUB>2</SUB> receptors mutated at position 256,&nbsp;we postulated<SUP> </SUP>that
transition to activated states of the B<SUB>2</SUB> receptor involves<SUP> </SUP>an increase in the representation of conformational states possessing<SUP> </SUP>a
Trp<SUP>256</SUP>-Phe<SUP>259</SUP> interaction (Fig. <a href="#F8">8</a>). This
hypothesis of intrahelical interaction<SUP> </SUP>is in agreement with previous
modeling studies of biogenic amine<SUP> </SUP>receptors pointing out the role of
TM</A> VI aromatic residues (<A HREF="#B30">30</A>,<SUP> </SUP><A HREF="#B49">49</A>) and data relative to the
<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>1<IMG SRC="/math/12pt/normal/scr/beta.gif" ALIGN=BOTTOM ALT="beta "></SUB> receptor activation
process.<A HREF="#FN2"><SUP>2</SUP></A>
    
    </P>

    
    <P>Concerning possible mechanistic connections between TM</A> VI and TM</A> VII
the question is raised whether the different behaviors<SUP> </SUP>of TM</A> VII
residues in the AT<SUB>1</SUB> and B<SUB>2</SUB> receptors, including
Tyr<SUP>292</SUP> and Tyr<SUP>295</SUP>, are related to differences
in the role of their TM</A> VI Trp residue,<SUP> </SUP><I>i.e.</I> inhibition of
hormone-induced activation for the AT<SUB>1</SUB> (<A HREF="#B5">5</A>)<SUP> </SUP>and constitutive
activation for the B<SUB>2</SUB> receptors. Relationships<SUP> </SUP>between the
roles of the two helices would be consistent with<SUP> </SUP>the presence of
hormone interaction sites near the extracellular<SUP> </SUP>ends of TM</A> VI and VII
of the AT<SUB>1</SUB> (<A HREF="#B50">50</A>, <A HREF="#B51">51</A>) and B<SUB>2</SUB> (<A HREF="#B52">52</A>, <A HREF="#B53">53</A>)<SUP> </SUP>receptors
and the finding that relative motions of TMs VI and<SUP> </SUP>VII participate in
the activation of muscarinic receptors (<A HREF="#B54">54</A>).<SUP> </SUP>The construction of
chimeric B<SUB>1</SUB>/B<SUB>2</SUB> receptors (<A HREF="#B55">55</A>) and point<SUP> </SUP>mutations in the B<SUB>1</SUB> receptor TMVII (<A HREF="#B56">56</A>) emphasize the role
of<SUP> </SUP>the 3rd extracellular loop and TM</A> VII, respectively, in the
specificity<SUP> </SUP>of ligand<SUP> </SUP>recognition.
    
    </P>

    
    <P>Although it is impossible to deduce from literature data general rules
about spatial restrains in inactive GPCR</A> conformations,<SUP> </SUP>many data
indicate that residues of TMs III and VI, some of which<SUP> </SUP>are located at
homologous or neighboring positions, have been<SUP> </SUP>identified as switch
residues, <I>i.e</I>. direct interaction sites for<SUP> </SUP>agonists whereby
these latter initiate destabilization of inactive<SUP> </SUP>conformations. For
instance, constitutive activation of the platelet-activating<SUP> </SUP>factor
receptor (<A HREF="#B57">57</A>), the <IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>1B</SUB> or <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>2</SUB>-adrenergic
receptors (<A HREF="#B58">58</A>,<SUP> </SUP><A HREF="#B59">59</A>), or the B<SUB>1</SUB> bradykinin receptor (<A HREF="#B28">28</A>)
could be induced by<SUP> </SUP>the mutation of an asparagine or a cysteine located
at the homologous<SUP> </SUP>position of the TM</A> III Asn of the AT<SUB>1</SUB> and
B<SUB>2</SUB> receptors. The role<SUP> </SUP>of this Asn is consistent with
membrane helix studies which emphasize<SUP> </SUP>that hydrogen bond interhelical
interactions can be driven by<SUP> </SUP>Asn residues (<A HREF="#B60">60-62</A>). Asn<SUP>111</SUP>
and His<SUP>256</SUP> were postulated to constitute AII interaction
points (<A HREF="#B16">16</A>) and<SUP> </SUP>are probably involved in the generation of the
AT<SUB>1</SUB> receptor intermediary<SUP> </SUP>conformational states (<A HREF="#B17">17</A>); that
Phe<SUP>259</SUP> is a BK-binding residue in the B<SUB>2</SUB>
receptor is consistent with<SUP> </SUP>the postulated role of this residue inside
the intramolecular<SUP> </SUP>interaction networks. Interestingly residues located
at the same<SUP> </SUP>position in TM</A> VI of other receptors control the activation
process<SUP> </SUP>and are involved in ligand binding: Phe<SUP>310</SUP> in the
<IMG SRC="/math/12pt/normal/alpha.gif" ALIGN=BOTTOM ALT="alpha "><SUB>1B</SUB> receptor (<A HREF="#B63">63</A>), Tyr<SUP>381</SUP> in the
M<SUB>1</SUB> muscarinic receptor (<A HREF="#B64">64</A>), and Tyr<SUP>282</SUP> in the
TRH receptor (<A HREF="#B26">26</A>). A systematic analysis of randomly<SUP> </SUP>mutated receptors
(<A HREF="#B2">2</A>, <A HREF="#B3">3</A>, <A HREF="#B65">65</A>) emphasize that other residues<SUP> </SUP>located in TMs III and VI are
involved: for instance, Phe<SUP>451</SUP> and Asn<SUP>459</SUP> in
the M<SUB>5</SUB> muscarinic receptor, homologous of the
Phe<SUP>252</SUP> and Gln<SUP>260</SUP> B<SUB>2</SUB><SUP> </SUP>residues.
    
    </P>

    
    <P>A second aspect of the present work was to establish the molecular
basis of nonpeptide ligand recognition and inactivation<SUP> </SUP>of the
B<SUB>2</SUB> bradykinin receptor. Structure-function analysis allowed<SUP> </SUP>precise essential nonpeptide-receptor contacts: the nonpeptide<SUP> </SUP>quinoline moiety interacts simultaneously with Tyr<SUP>295</SUP> and
Trp<SUP>256</SUP>. Gln<SUP>288</SUP> is also involved in ligand
binding. On this basis we could propose<SUP> </SUP>a docking of the nonpeptidic
ligand LF 16-0687&nbsp;either in a receptor<SUP> </SUP>model homology deduced from a
previous AT<SUB>1</SUB> model (experimental<SUP> </SUP>model) or in a model
derived from the rhodopsin structure (rhodopsin-like<SUP> </SUP>structure). It is
noteworthy that B<SUB>2</SUB> receptor nonpeptide antagonists<SUP> </SUP>studied
in the present work interact with residues of TM</A> VI and<SUP> </SUP>VII, possibly
restricting movements of these helices required<SUP> </SUP>for activation,
together with helix III movements. The nonpeptide<SUP> </SUP>interaction with
these residues, with a major "locking" role of<SUP> </SUP>the sandwich
interaction of their quinoline moiety with Trp<SUP>256</SUP> and
Tyr<SUP>295</SUP>, might restrain the essential Trp<SUP>256</SUP> in
a position favorable to its interaction with Asn<SUP>113</SUP> which
constitutes the cornerstone of inactive conformations.<SUP> </SUP>This
stabilizing effect would provide an explanation for the inverse<SUP> </SUP>agonist
behavior of this ligand and its agonist behavior on the<SUP> </SUP>CAM</A> N113A and
W256F receptors which no longer possesses the Asn-Trp<SUP> </SUP>interaction; in
this latter situation the high conformational<SUP> </SUP>flexibility of the
nonpeptidic derivatives would allow them to<SUP> </SUP>fit with or induce CAM</A>
receptor active<SUP> </SUP>conformations.
    
    </P>

    
    <P>Interestingly the B<SUB>2</SUB> receptor residues involved in
nonpeptide recognition are somehow involved in receptor activation even<SUP> </SUP>if the precise role of some of them, located at key positions<SUP> </SUP>in other
GPCR</A>, requires further elucidation. It indicates that<SUP> </SUP>ligands
synthesized through semiempirical strategies have been<SUP> </SUP>implicitly
selected according to their ability to interact with<SUP> </SUP>receptor residues
which control conformational equilibria. Similar<SUP> </SUP>conclusions can be
drawn for the AT<SUB>1</SUB> receptor, inasmuch Asn<SUP>111</SUP> and
His<SUP>256</SUP>, which are switch residues for AII action, are
involved in losartan<SUP> </SUP>and other nonpeptide ligand binding (together with
Asn<SUP>295</SUP> in TM</A> VII) (<A HREF="#B5">5</A>, <A HREF="#B14">14</A>, <A HREF="#B66">66</A>, <A HREF="#B67">67</A>). The NK<SUB>2</SUB>
receptor amino acid<SUP> </SUP>Tyr<SUP>266</SUP>, homologous to the
AT<SUB>1</SUB> receptor His<SUP>256</SUP>, was shown to participate
in peptide agonist and nonpeptide antagonist<SUP> </SUP>binding (<A HREF="#B68">68</A>). The question
is raised whether such considerations<SUP> </SUP>should be taken into account for
future attempts of rational design<SUP> </SUP>of nonpeptidic GPCR</A> ligands.
Experimental evaluation of the conformational<SUP> </SUP>flexibility of GPCR</A> (<A HREF="#B1">1</A>)
and the ability of ligands to induce<SUP> </SUP>specific conformational changes
will probably constitute a major<SUP> </SUP>difficulty in future structure
predictions from the rhodopsin<SUP> </SUP>crystallographic data (<A HREF="#B11">11</A>). Conflicting
results were reported<SUP> </SUP>about the extent of structural changes associated
to rhodopsin<SUP> </SUP>activation (<A HREF="#B33">33</A>, <A HREF="#B69">69</A>). A recent reassessment of
catecholamine<SUP> </SUP>action on the <IMG SRC="/math/12pt/normal/beta.gif" ALIGN=BOTTOM ALT="beta "><SUB>2</SUB>-adrenergic receptor (<A HREF="#B70">70</A>)
demonstrates the usefulness<SUP> </SUP>of thermodynamic studies to dissect ligand
action in terms of<SUP> </SUP>receptor binding and modulation of conformational
equilibria.<SUP> </SUP>Taken together our data emphasize the role of
B<SUB>2</SUB> receptor key<SUP> </SUP>residues which control conformational
equilibria and constitute<SUP> </SUP>ligand interaction points and are located at
strategic positions<SUP> </SUP>for the function of other GPCR</A>, including<SUP> </SUP>rhodopsin.
    
    


<BR><BR CLEAR=ALL>

</TXT>



<!-- Stray figures and tables -->


<!-- Acknowledgements -->

<A NAME="ack"><!-- comment for mosaic --></A>

<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;ACKNOWLEDGEMENTS</FONT></TH>
</TR>
</TABLE>


<P>We thank J.&nbsp;L.&nbsp;Borgna and J.&nbsp;C.&nbsp;Nicolas for reading the manuscript and helpful<SUP> </SUP>advice.
</P>

<!-- Notes -->


<!-- Footnotes -->

<A NAME="foo"><!-- comment for mosaic --></A>

<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;FOOTNOTES</FONT></TH>
</TR>
</TABLE>



<P><A NAME="FN150"><SUP>*</SUP></A>
This work was supported by the Institut National de la
Sant&eacute; et de la Recherche M&eacute;dicale, Center National de la
Recherche<SUP> </SUP>Scientifique (including "Mol&eacute;cules et Cibles
Th&eacute;rapeutiques"<SUP> </SUP>and "Physique et Chimie du Vivant"
programs), Laboratoires Fournier<SUP> </SUP>(Daix, France), and Fondation pour la
Recherche M&eacute;dicale.The<SUP> </SUP>costs of publication of this
article were defrayed in part by<SUP> </SUP>the
payment of page charges. The article
must therefore be hereby<SUP> </SUP>marked
"<I>advertisement</I>" in
accordance with 18&nbsp;U.S.C. Section
1734<SUP>&nbsp;</SUP>solely to indicate this<SUP> </SUP>fact.

<P>
<P><A NAME="FN154"><SUP>&#182;</SUP></A>
Supported by fellowships from the Minist&egrave;re de
l'Enseignement Sup&eacute;rieur et de la Recherche and Association pour
la Recherche<SUP> </SUP>contre le Cancer. Present address: AstraZeneca, 7171&nbsp;Fr&eacute;d&eacute;rick-Banting,<SUP> </SUP>Ville Saint-Laurent (Montr&eacute;al),
Qu&eacute;bec H4S 1Z,<SUP> </SUP>Canada.

<P>
<P><A NAME="FN160"><SUP>**</SUP></A>
To whom correspondence should be<SUP> </SUP>addressed.

<P>


<P>
Published, JBC Papers in Press, August 8,&nbsp;2001,&nbsp;DOI 10.1074/jbc.M104875200

<P>
<P><A NAME="FN2"><SUP>2</SUP></A>
S. Cotecchia, unpublished<SUP> </SUP>results.

<P>

<A NAME="abb"><!-- comment for mosaic --></A>

<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;ABBREVIATIONS</FONT></TH>
</TR>
</TABLE>

<P>The abbreviations used are: 

GPCR, G-protein
coupled receptor;

WT, wild-type;

TM, transmembrane domain;

CAM, constitutively activated mutant;

AII: angiotensin II, BK, bradykinin;

IP, inositol phosphate.

</P>


<!-- Appendices -->

<!-- Bibliography -->




<A NAME="References"><!-- null --></A>
<TABLE WIDTH=100% BGCOLOR=E1E1E1 CELLPADDING=0 CELLSPACING=0>
<TR>
<TD ALIGN=LEFT VALIGN=MIDDLE WIDTH=5% BGCOLOR=FFFFFF>&nbsp;<IMG WIDTH=10 HEIGHT=21 HSPACE=5 ALT="" SRC="/icons/toc/rarrow.gif"></TD>
<TH ALIGN=LEFT VALIGN=MIDDLE WIDTH=95%><FONT SIZE=+2>&nbsp;&nbsp;REFERENCES</FONT></TH>
</TR>
</TABLE>

<TABLE ALIGN=RIGHT CELLPADDING=5 BORDER NOWRAP><R>
<TH ALIGN=LEFT>
<FONT SIZE=-1>



<A HREF="#Top"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">TOP</A>


<BR>
<A HREF="#Abstract"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">ABSTRACT</A>


<BR>
<A HREF="#Introduction"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">INTRODUCTION</A>


<BR>
<A HREF="#SEC1"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">EXPERIMENTAL PROCEDURES</A>


<BR>
<A HREF="#SEC2"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">RESULTS</A>


<BR>
<A HREF="#SEC3"><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/uarrow.gif">DISCUSSION</A>


<BR><IMG WIDTH=11 HEIGHT=9 BORDER=0 HSPACE=5 SRC="/icons/toc/dot.gif"><FONT COLOR=46
4C53>REFERENCES</FONT>
</FONT></TH>
</TR></TABLE>

<BR CLEAR=ALL>
<TABLE BORDER=0>
<TR><TD VALIGN=TOP><a name="B1">1.</a>
    <TD VALIGN=TOP>

Gether, U.



(2000)

<I>Endocr. Rev.</I>
<B>21</B>,
90-113<!-- HIGHWIRE ID="276:44:41100:1" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=edrv&resid=21/1/90" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B2">2.</a>
    <TD VALIGN=TOP>

Lu, Z. L.,
 and Hulme, E. C.



(1999)

<I>J. Biol. Chem.</I>
<B>274</B>,
7309-7315<!-- HIGHWIRE ID="276:44:41100:2" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=274/11/7309" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B3">3.</a>
    <TD VALIGN=TOP>

Spalding, T. A.,
Burstein, E. S.,
Henderson, S. C.,
Ducote, K. R.,
 and Brann, M. R.



(1998)

<I>J. Biol. Chem.</I>
<B>273</B>,
21563-21568<!-- HIGHWIRE ID="276:44:41100:3" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=273/34/21563" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B4">4.</a>
    <TD VALIGN=TOP>

Marie, J.,
Koch, C.,
Pruneau, D.,
Paquet, J. L.,
Groblewski, T.,
Larguier, R.,
Lombard, C.,
Deslauriers, B.,
Maigret, B.,
 and Bonnafous, J. C.



(1999)

<I>Mol. Pharmacol.</I>
<B>55</B>,
92-101<!-- HIGHWIRE ID="276:44:41100:4" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=55/1/92" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B5">5.</a>
    <TD VALIGN=TOP>Groblewski, T.&nbsp;(1997) <I>Health Biology,</I> Ph. D.&nbsp;Thesis,
Montpellier
    <!-- HIGHWIRE ID="276:44:41100:5" --><!-- /HIGHWIRE --></TR>
<TR><TD VALIGN=TOP><a name="B6">6.</a>
    <TD VALIGN=TOP>

Groblewski, T.,
Maigret, B.,
Larguier, R.,
Lombard, C.,
Bonnafous, J. C.,
 and Marie, J.



(1997)

<I>J. Biol. Chem.</I>
<B>272</B>,
1822-1866<!-- HIGHWIRE ID="276:44:41100:6" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=272/3/1822" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B7">7.</a>
    <TD VALIGN=TOP>

Pruneau, D.,
Luccarini, J. M.,
Fouchet, C.,
Defrene, E.,
Franck, R. M.,
Loillier, B.,
Duclos, H.,
Robert, C.,
Cremers, B.,
Belichard, P.,
 and Paquet, J. L.



(1998)

<I>Br. J.&nbsp;Pharmacol.</I>
<B>125</B>,
365-372<!-- HIGHWIRE ID="276:44:41100:7" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=brjpharmacol&resid=125/2/365" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B8">8.</a>
    <TD VALIGN=TOP>

Pruneau, D.,
Paquet, J. L.,
Luccarini, J. M.,
Defrene, E.,
Fouchet, C.,
Franck, R. M.,
Loillier, B.,
Robert, C.,
Belichard, P.,
Duclos, H.,
Cremers, B.,
 and Dodey, P.



(1999)

<I>Immunopharmacology</I>
<B>43</B>,
187-194<!-- HIGHWIRE ID="276:44:41100:8" --><A HREF="/cgi/external_ref?access_num=10.1016/S0162-3109(99)00128-9&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10596852&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10596852&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B9">9.</a>
    <TD VALIGN=TOP>

Baldwin, J. M.,
Schertler, G. F.,
 and Unger, V. M.



(1997)

<I>J. Mol. Biol.</I>
<B>272</B>,
144-164<!-- HIGHWIRE ID="276:44:41100:9" --><A HREF="/cgi/external_ref?access_num=10.1006/jmbi.1997.1240&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9299344&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9299344&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B10">10.</a>
    <TD VALIGN=TOP>

Herzyk, P.,
 and Hubbard, R. E.



(1998)

<I>J. Mol. Biol.</I>
<B>281</B>,
741-754<!-- HIGHWIRE ID="276:44:41100:10" --><A HREF="/cgi/external_ref?access_num=10.1006/jmbi.1998.1981&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9710543&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9710543&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B11">11.</a>
    <TD VALIGN=TOP>

Palczewski, K.,
Kumasaka, T.,
Hori, T.,
Behnke, C. A.,
Motoshima, H.,
Fox, B. A.,
Le Trong, I.,
Teller, D. C.,
Okada, T.,
Stenkamp, R. E.,
Yamamoto, M.,
 and Miyano, M.



(2000)

<I>Science</I>
<B>289</B>,
739-745<!-- HIGHWIRE ID="276:44:41100:11" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=sci&resid=289/5480/739" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B12">12.</a>
    <TD VALIGN=TOP>

Hess, J. F.,
Borkowski, J. A.,
Young, G. S.,
Strader, C. D.,
 and Ransom, R. W.



(1992)

<I>Biochem. Biophys. Res. Commun.</I>
<B>184</B>,
260-268<!-- HIGHWIRE ID="276:44:41100:12" --><A HREF="/cgi/external_ref?access_num=1314587&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=1314587&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B13">13.</a>
    <TD VALIGN=TOP>

Joseph, M. P.,
Maigret, B.,
Bonnafous, J. C.,
Marie, J.,
 and Scheraga, H. A.



(1995)

<I>J. Protein Chem.</I>
<B>14</B>,
381-398<!-- HIGHWIRE ID="276:44:41100:13" --><A HREF="/cgi/external_ref?access_num=8590606&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=8590606&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B14">14.</a>
    <TD VALIGN=TOP>

Noda, K.,
Saad, Y.,
Kinoshita, A.,
Boyle, T. P.,
Graham, R. M.,
Husain, A.,
 and Karnik, S. S.



(1995)

<I>J. Biol. Chem.</I>
<B>270</B>,
2284-2289<!-- HIGHWIRE ID="276:44:41100:14" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=270/5/2284" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B15">15.</a>
    <TD VALIGN=TOP>

Marie, J.,
Maigret, B.,
Joseph, M. P.,
Larguier, R.,
Nouet, S.,
Lombard, C.,
 and Bonnafous, J. C.



(1994)

<I>J. Biol. Chem.</I>
<B>269</B>,
20815-20818<!-- HIGHWIRE ID="276:44:41100:15" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=269/33/20815" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B16">16.</a>
    <TD VALIGN=TOP>

Noda, K.,
Saad, Y.,
 and Karnik, S. S.



(1995)

<I>J. Biol. Chem.</I>
<B>270</B>,
28511-28514<!-- HIGHWIRE ID="276:44:41100:16" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=270/48/28511" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B17">17.</a>
    <TD VALIGN=TOP>

Noda, K.,
Feng, Y. H.,
Liu, X. P.,
Saad, Y.,
Husain, A.,
 and Karnik, S. S.



(1996)

<I>Biochemistry</I>
<B>35</B>,
16435-16442<!-- HIGHWIRE ID="276:44:41100:17" --><A HREF="/cgi/external_ref?access_num=10.1021/bi961593m&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=8987975&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=8987975&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B18">18.</a>
    <TD VALIGN=TOP>

Miura, S.,
Feng, Y. H.,
Husain, A.,
 and Karnik, S. S.



(1999)

<I>J. Biol. Chem.</I>
<B>274</B>,
7103-7110<!-- HIGHWIRE ID="276:44:41100:18" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=274/11/7103" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B19">19.</a>
    <TD VALIGN=TOP>

Jarnagin, K.,
Bhakta, S.,
Zuppan, P.,
Yee, C.,
Ho, T.,
Phan, T.,
Tahilramani, R.,
Pease, J. H.,
Miller, A.,
 and Freedman, R.



(1996)

<I>J. Biol. Chem.</I>
<B>271</B>,
28277-28286<!-- HIGHWIRE ID="276:44:41100:19" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=271/45/28277" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B20">20.</a>
    <TD VALIGN=TOP>

Konopka, J. B.,
Margarit, S. M.,
 and Dube, P.



(1996)

<I>Proc. Natl. Acad. Sci. U.&nbsp;S.&nbsp;A.</I>
<B>93</B>,
6764-6769<!-- HIGHWIRE ID="276:44:41100:20" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=93/13/6764" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B21">21.</a>
    <TD VALIGN=TOP>

Fathy, D. B.,
Mathis, S. A.,
Leeb, T.,
 and Leeb-Lundberg, L. M.



(1998)

<I>J. Biol. Chem.</I>
<B>273</B>,
12210-12218<!-- HIGHWIRE ID="276:44:41100:21" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=273/20/12210" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B22">22.</a>
    <TD VALIGN=TOP>

Scheer, A.,
Fanelli, F.,
Costa, T.,
De Benedetti, P. G.,
 and Cotecchia, S.



(1996)

<I>EMBO J.</I>
<B>15</B>,
3566-3578<!-- HIGHWIRE ID="276:44:41100:22" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=emboj&resid=15/14/3566" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B23">23.</a>
    <TD VALIGN=TOP>

Perlman, J. H.,
Colson, A. O.,
Wang, W.,
Bence, K.,
Osman, R.,
 and Gershengorn, M. C.



(1997)

<I>J. Biol. Chem.</I>
<B>272</B>,
11937-11942<!-- HIGHWIRE ID="276:44:41100:23" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=272/18/11937" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B24">24.</a>
    <TD VALIGN=TOP>

Ballesteros, J.,
Kitanovic, S.,
Guarnieri, F.,
Davies, P.,
Fromme, B. J.,
Konvicka, K.,
Chi, L.,
Millar, R. P.,
Davidson, J. S.,
Weinstein, H.,
 and Sealfon, S. C.



(1998)

<I>J. Biol. Chem.</I>
<B>273</B>,
10445-10453<!-- HIGHWIRE ID="276:44:41100:24" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=273/17/10445" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B25">25.</a>
    <TD VALIGN=TOP>

Zhou, W.,
Flanagan, C.,
Ballesteros, J. A.,
Konvicka, K.,
Davidson, J. S.,
Weinstein, H.,
Millar, R. P.,
 and Sealfon, S. C.



(1994)

<I>Mol. Pharmacol.</I>
<B>45</B>,
165-170<!-- HIGHWIRE ID="276:44:41100:25" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=45/2/165" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B26">26.</a>
    <TD VALIGN=TOP>

Colson, A. O.,
Perlman, J. H.,
Jinsi-Parimoo, A.,
Nussenzveig, D. R.,
Osman, R.,
 and Gershengorn, M. C.



(1998)

<I>Mol. Pharmacol.</I>
<B>54</B>,
968-978<!-- HIGHWIRE ID="276:44:41100:26" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=54/6/968" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B27">27.</a>
    <TD VALIGN=TOP>

Hunyady, L.,
Ji, H.,
Jagadeesh, G.,
Zhang, M.,
Gaborik, Z.,
Mihalik, B.,
 and Catt, K. J.



(1998)

<I>Mol. Pharmacol.</I>
<B>54</B>,
427-434<!-- HIGHWIRE ID="276:44:41100:27" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=54/2/427" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B28">28.</a>
    <TD VALIGN=TOP>

Leeb-Lundberg, L. M.,
Kang, D. S.,
Lamb, M. E.,
 and Fathy, D. B.



(2001)

<I>J. Biol. Chem.</I>
<B>276</B>,
8785-8792<!-- HIGHWIRE ID="276:44:41100:28" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=276/12/8785" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B29">29.</a>
    <TD VALIGN=TOP>

Rosenkilde, M. M.,
 and Schwartz, T. W.



(2000)

<I>Mol. Pharmacol.</I>
<B>57</B>,
602-609<!-- HIGHWIRE ID="276:44:41100:29" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=57/3/602" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B30">30.</a>
    <TD VALIGN=TOP>

Bikker, J. A.,
Trumpp-Kallmeyer, S.,
 and Humblet, C.



(1998)

<I>J. Med. Chem.</I>
<B>41</B>,
2911-2927<!-- HIGHWIRE ID="276:44:41100:30" --><A HREF="/cgi/external_ref?access_num=10.1021/jm970767a&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9685229&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9685229&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B31">31.</a>
    <TD VALIGN=TOP>

Pogozheva, I. D.,
Lomize, A. L.,
 and Mosberg, H. I.



(1997)

<I>Biophys. J.</I>
<B>72</B>,
1963-1985<!-- HIGHWIRE ID="276:44:41100:31" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=biophysj&resid=72/5/1963" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B32">32.</a>
    <TD VALIGN=TOP>

Nakayama, T. A.,
 and Khorana, H. G.



(1990)

<I>J. Biol. Chem.</I>
<B>265</B>,
15762-15769<!-- HIGHWIRE ID="276:44:41100:32" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=265/26/15762" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B33">33.</a>
    <TD VALIGN=TOP>

Borhan, B.,
Souto, M. L.,
Imai, H.,
Shichida, Y.,
 and Nakanishi, K.



(2000)

<I>Science</I>
<B>288</B>,
2209-2212<!-- HIGHWIRE ID="276:44:41100:33" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=sci&resid=288/5474/2209" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B34">34.</a>
    <TD VALIGN=TOP>

Befort, K.,
Zilliox, C.,
Filliol, D.,
Yue, S.,
 and Kieffer, B. L.



(1999)

<I>J. Biol. Chem.</I>
<B>274</B>,
18574-18581<!-- HIGHWIRE ID="276:44:41100:34" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=274/26/18574" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B35">35.</a>
    <TD VALIGN=TOP>

Imai, H.,
Kojima, D.,
Oura, T.,
Tachibanaki, S.,
Terakita, A.,
 and Shichida, Y.



(1997)

<I>Proc. Natl. Acad. Sci. U.&nbsp;S.&nbsp;A.</I>
<B>94</B>,
2322-2326<!-- HIGHWIRE ID="276:44:41100:35" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=94/6/2322" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B36">36.</a>
    <TD VALIGN=TOP>

Beck, M.,
Sakmar, T. P.,
 and Siebert, F.



(1998)

<I>Biochemistry</I>
<B>37</B>,
7630-7639<!-- HIGHWIRE ID="276:44:41100:36" --><A HREF="/cgi/external_ref?access_num=10.1021/bi9801560&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9585578&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9585578&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B37">37.</a>
    <TD VALIGN=TOP>

Nagata, T.,
Terakita, A.,
Kandori, H.,
Shichida, Y.,
 and Maeda, A.



(1998)

<I>Biochemistry</I>
<B>37</B>,
17216-17222<!-- HIGHWIRE ID="276:44:41100:37" --><A HREF="/cgi/external_ref?access_num=10.1021/bi9810149&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9860835&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9860835&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B38">38.</a>
    <TD VALIGN=TOP>

Maeda, A.,
Tomson, F. L.,
Gennis, R. B.,
Kandori, H.,
Ebrey, T. G.,
 and Balashov, S. P.



(2000)

<I>Biochemistry</I>
<B>39</B>,
10154-10162<!-- HIGHWIRE ID="276:44:41100:38" --><A HREF="/cgi/external_ref?access_num=10.1021/bi000190q&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10956004&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10956004&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B39">39.</a>
    <TD VALIGN=TOP>

Royant, A.,
Edman, K.,
Ursby, T.,
Pebay-Peyroula, E.,
Landau, E. M.,
 and Neutze, R.



(2000)

<I>Nature</I>
<B>406</B>,
645-648<!-- HIGHWIRE ID="276:44:41100:39" --><A HREF="/cgi/external_ref?access_num=10.1038/35020599&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10949307&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10949307&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B40">40.</a>
    <TD VALIGN=TOP>

Sass, H. J.,
Buldt, G.,
Gessenich, R.,
Hehn, D.,
Neff, D.,
Schlesinger, R.,
Berendzen, J.,
 and Ormos, P.



(2000)

<I>Nature</I>
<B>406</B>,
649-653<!-- HIGHWIRE ID="276:44:41100:40" --><A HREF="/cgi/external_ref?access_num=10.1038/35020607&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10949308&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10949308&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B41">41.</a>
    <TD VALIGN=TOP>

Subramaniam, S.,
Lindahl, M.,
Bullough, P.,
Faruqi, A. R.,
Tittor, J.,
Oesterhelt, D.,
Brown, L.,
Lanyi, J.,
 and Henderson, R.



(1999)

<I>J. Mol. Biol.</I>
<B>287</B>,
145-161<!-- HIGHWIRE ID="276:44:41100:41" --><A HREF="/cgi/external_ref?access_num=10.1006/jmbi.1999.2589&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10074413&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10074413&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B42">42.</a>
    <TD VALIGN=TOP>

Subramaniam, S.,
 and Henderson, R.



(2000)

<I>Nature</I>
<B>406</B>,
653-657<!-- HIGHWIRE ID="276:44:41100:42" --><A HREF="/cgi/external_ref?access_num=10.1038/35020614&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10949309&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10949309&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B43">43.</a>
    <TD VALIGN=TOP>

Luecke, H.,
Schobert, B.,
Cartailler, J. P.,
Richter, H. T.,
Rosengarth, A.,
Needleman, R.,
 and Lanyi, J. K.



(2000)

<I>J. Mol. Biol.</I>
<B>300</B>,
1237-1255<!-- HIGHWIRE ID="276:44:41100:43" --><A HREF="/cgi/external_ref?access_num=10.1006/jmbi.2000.3884&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10903866&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10903866&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B44">44.</a>
    <TD VALIGN=TOP>

Vogel, R.,
Fan, G. B.,
Sheves, M.,
 and Siebert, F.



(2000)

<I>Biochemistry</I>
<B>39</B>,
8895-8908<!-- HIGHWIRE ID="276:44:41100:44" --><A HREF="/cgi/external_ref?access_num=10.1021/bi000852b&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10913302&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10913302&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B45">45.</a>
    <TD VALIGN=TOP>

Han, M.,
Groesbeek, M.,
Smith, S. O.,
 and Sakmar, T. P.



(1998)

<I>Biochemistry</I>
<B>37</B>,
538-545<!-- HIGHWIRE ID="276:44:41100:45" --><A HREF="/cgi/external_ref?access_num=10.1021/bi972060w&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=9425074&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=9425074&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B46">46.</a>
    <TD VALIGN=TOP>

Gether, U.,
 and Kobilka, B. K.



(1998)

<I>J. Biol. Chem.</I>
<B>273</B>,
17979-17982<!-- HIGHWIRE ID="276:44:41100:46" --><A HREF="/cgi/ijlink?linkType=FULL&journalCode=jbc&resid=273/29/17979" ><nobr>[<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B47">47.</a>
    <TD VALIGN=TOP>

Elling, C. E.,
Thirstrup, K.,
Holst, B.,
 and Schwartz, T. W.



(1999)

<I>Proc. Natl. Acad. Sci. U.&nbsp;S.&nbsp;A.</I>
<B>96</B>,
12322-12327<!-- HIGHWIRE ID="276:44:41100:47" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=96/22/12322" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B48">48.</a>
    <TD VALIGN=TOP>

Holst, B.,
Elling, C. E.,
 and Schwartz, T. W.



(2000)

<I>Mol. Pharmacol.</I>
<B>58</B>,
263-270<!-- HIGHWIRE ID="276:44:41100:48" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=58/2/263" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B49">49.</a>
    <TD VALIGN=TOP>

Befort, K.,
Tabbara, L.,
Kling, D.,
Maigret, B.,
 and Kieffer, B. L.



(1996)

<I>J. Biol. Chem.</I>
<B>271</B>,
10161-10168<!-- HIGHWIRE ID="276:44:41100:49" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=271/17/10161" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B50">50.</a>
    <TD VALIGN=TOP>

Feng, Y. H.,
Noda, K.,
Saad, Y.,
Liu, X. P.,
Husain, A.,
 and Karnik, S. S.



(1995)

<I>J. Biol. Chem.</I>
<B>270</B>,
12846-12850<!-- HIGHWIRE ID="276:44:41100:50" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=270/21/12846" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B51">51.</a>
    <TD VALIGN=TOP>

Hjorth, S. A.,
Schambye, H. T.,
Greenlee, W. J.,
 and Schwartz, T. W.



(1994)

<I>J. Biol. Chem.</I>
<B>269</B>,
30953-30959<!-- HIGHWIRE ID="276:44:41100:51" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=269/49/30953" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B52">52.</a>
    <TD VALIGN=TOP>

Nardone, J.,
 and Hogan, P. G.



(1994)

<I>Proc. Natl. Acad. Sci. U.&nbsp;S.&nbsp;A.</I>
<B>91</B>,
4417-4421<!-- HIGHWIRE ID="276:44:41100:52" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=pnas&resid=91/10/4417" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B53">53.</a>
    <TD VALIGN=TOP>

Kyle, D. J.,
Chakravarty, S.,
Sinsko, J. A.,
 and Stormann, T. M.



(1994)

<I>J. Med. Chem.</I>
<B>37</B>,
1347-1354<!-- HIGHWIRE ID="276:44:41100:53" --><A HREF="/cgi/external_ref?access_num=7909848&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=7909848&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B54">54.</a>
    <TD VALIGN=TOP>

Huang, X. P.,
Williams, F. E.,
Peseckis, S. M.,
 and Messer, W. S.



(1999)

<I>Mol Pharmacol</I>
<B>56</B>,
775-783<!-- HIGHWIRE ID="276:44:41100:54" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=56/4/775" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B55">55.</a>
    <TD VALIGN=TOP>

Fathy, D. B.,
Kyle, D. J.,
 and Leeb-Lundberg, L. M.



(2000)

<I>Mol. Pharmacol.</I>
<B>57</B>,
171-179<!-- HIGHWIRE ID="276:44:41100:55" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=57/1/171" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B56">56.</a>
    <TD VALIGN=TOP>

Bastian, S.,
Pruneau, D.,
Loillier, B.,
Robert, C.,
Bonnafous, J. C.,
 and Paquet, J. L.



(2000)

<I>J. Biol. Chem.</I>
<B>275</B>,
6107-6113<!-- HIGHWIRE ID="276:44:41100:56" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=275/9/6107" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B57">57.</a>
    <TD VALIGN=TOP>

Ishii, I.,
Izumi, T.,
Tsukamoto, H.,
Umeyama, H.,
Ui, M.,
 and Shimizu, T.



(1997)

<I>J. Biol. Chem.</I>
<B>272</B>,
7846-7854<!-- HIGHWIRE ID="276:44:41100:57" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=272/12/7846" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B58">58.</a>
    <TD VALIGN=TOP>

Zuscik, M. J.,
Porter, J. E.,
Gaivin, R.,
 and Perez, D. M.



(1998)

<I>J. Biol. Chem.</I>
<B>273</B>,
3401-3407<!-- HIGHWIRE ID="276:44:41100:58" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=273/6/3401" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B59">59.</a>
    <TD VALIGN=TOP>

Perez, D. M.,
Hwa, J.,
Gaivin, R.,
Mathur, M.,
Brown, F.,
 and Graham, R. M.



(1996)

<I>Mol. Pharmacol.</I>
<B>49</B>,
112-122<!-- HIGHWIRE ID="276:44:41100:59" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=49/1/112" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B60">60.</a>
    <TD VALIGN=TOP>

Pace, C. N.



(2001)

<I>Biochemistry</I>
<B>40</B>,
310-313<!-- HIGHWIRE ID="276:44:41100:60" --><A HREF="/cgi/external_ref?access_num=10.1021/bi001574j&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=11148023&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=11148023&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B61">61.</a>
    <TD VALIGN=TOP>

Choma, C.,
Gratkowski, H.,
Lear, J. D.,
 and DeGrado, W. F.



(2000)

<I>Nat. Struct. Biol.</I>
<B>7</B>,
161-166<!-- HIGHWIRE ID="276:44:41100:61" --><A HREF="/cgi/external_ref?access_num=10.1038/72440&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10655620&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10655620&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B62">62.</a>
    <TD VALIGN=TOP>

Zhou, F. X.,
Cocco, M. J.,
Russ, W. P.,
Brunger, A. T.,
 and Engelman, D. M.



(2000)

<I>Nat. Struct. Biol.</I>
<B>7</B>,
154-160<!-- HIGHWIRE ID="276:44:41100:62" --><A HREF="/cgi/external_ref?access_num=10.1038/72430&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10655619&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10655619&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B63">63.</a>
    <TD VALIGN=TOP>

Chen, S.,
Xu, M.,
Lin, F.,
Lee, D.,
Riek, P.,
 and Graham, R. M.



(1999)

<I>J. Biol. Chem.</I>
<B>274</B>,
16320-16330<!-- HIGHWIRE ID="276:44:41100:63" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=274/23/16320" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B64">64.</a>
    <TD VALIGN=TOP>

Ward, S. D.,
Curtis, C. A.,
 and Hulme, E. C.



(1999)

<I>Mol. Pharmacol.</I>
<B>56</B>,
1031-1041<!-- HIGHWIRE ID="276:44:41100:64" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=56/5/1031" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B65">65.</a>
    <TD VALIGN=TOP>

Baranski, T. J.,
Herzmark, P.,
Lichtarge, O.,
Gerber, B. O.,
Trueheart, J.,
Meng, E. C.,
Iiri, T.,
Sheikh, S. P.,
 and Bourne, H. R.



(1999)

<I>J. Biol. Chem.</I>
<B>274</B>,
15757-15765<!-- HIGHWIRE ID="276:44:41100:65" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=jbc&resid=274/22/15757" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B66">66.</a>
    <TD VALIGN=TOP>

Groblewski, T.,
Maigret, B.,
Nouet, S.,
Larguier, R.,
Lombard, C.,
Bonnafous, J. C.,
 and Marie, J.



(1995)

<I>Biochem. Biophys. Res. Commun.</I>
<B>209</B>,
153-160<!-- HIGHWIRE ID="276:44:41100:66" --><A HREF="/cgi/external_ref?access_num=10.1006/bbrc.1995.1483&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=7726829&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=7726829&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B67">67.</a>
    <TD VALIGN=TOP>

Schambye, H. T.,
Hjorth, S. A.,
Weinstock, J.,
 and Schwartz, T. W.



(1995)

<I>Mol. Pharmacol.</I>
<B>47</B>,
425-431<!-- HIGHWIRE ID="276:44:41100:67" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=47/3/425" >[Abstract]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B68">68.</a>
    <TD VALIGN=TOP>

Huang, R. R.,
Vicario, P. P.,
Strader, C. D.,
 and Fong, T. M.



(1995)

<I>Biochemistry</I>
<B>34</B>,
10048-1055<!-- HIGHWIRE ID="276:44:41100:68" --><A HREF="/cgi/external_ref?access_num=7543277&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=7543277&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B69">69.</a>
    <TD VALIGN=TOP>

Struthers, M., Yu, H.,
 and Oprian, D. D.



(2000)

<I>Biochemistry</I>
<B>39</B>,
7938-7942<!-- HIGHWIRE ID="276:44:41100:69" --><A HREF="/cgi/external_ref?access_num=10.1021/bi000771f&link_type=DOI" >[CrossRef]</A><A HREF="/cgi/external_ref?access_num=10891074&link_type=MED">[Medline]</A> 
<A HREF="/cgi/external_ref?access_num=10891074&displayid=77141&link_type=INFOTRIEVE">[Order&nbsp;article&nbsp;via&nbsp;Infotrieve]</A><!-- /HIGHWIRE -->
    </TR>
<TR><TD VALIGN=TOP><a name="B70">70.</a>
    <TD VALIGN=TOP>

Ambrosio, C.,
Molinari, P.,
Cotecchia, S.,
 and Costa, T.



(2000)

<I>Mol. Pharmacol.</I>
<B>57</B>,
198-210<!-- HIGHWIRE ID="276:44:41100:70" --><A HREF="/cgi/ijlink?linkType=ABST&journalCode=molpharm&resid=57/1/198" ><nobr>[Abstract/<font COLOR="CC0000">Free</font> Full&nbsp;Text]</nobr></A><!-- /HIGHWIRE -->
    </TR>

</TABLE>



<P><HR>
<FONT SIZE=-1><A HREF="/misc/terms.shtml"><B>Copyright &#169; 2001 by The American Society for Biochemistry and Molecular Biology, Inc.</B></A></FONT>




<!--

   Pages created by the Electronic Press Engine from

		Atypon Systems, Inc.

   Visit http://www.atypon.com/

-->


</vardef>

		
        
        
	
	
	
	



 




<BR CLEAR=ALL>



  <FONT FACE="">
  
  </FONT>
<BR CLEAR=ALL>
<BR CLEAR=ALL>



<A NAME="otherarticles"><!-- null --></A>
<P>
<FONT SIZE=+2><STRONG>This article has been cited by other articles:</STRONG></FONT>
<P>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	X. Lu, W. Huang, S. Worthington, P. Drabik, R. Osman, and M. C. Gershengorn<BR>
	<STRONG>A Model of Inverse Agonist Action at Thyrotropin-Releasing Hormone Receptor Type 1: Role of a Conserved Tryptophan in Helix 6</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        November&nbsp;1,&nbsp;2004;
	66(5):
	1192 - 1200.
<BR>
<A HREF="http://www.molpharm.org/cgi/content/abstract/66/5/1192">[Abstract]</A>

<A HREF="http://www.molpharm.org/cgi/content/full/66/5/1192">[Full Text]</A>
<A HREF="http://www.molpharm.org/cgi/reprint/66/5/1192">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://edrv.endojournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://edrv.endojournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://edrv.endojournals.org"><IMG ALT="Endocr Rev" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/edrv.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	R. P. Millar, Z.-L. Lu, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley<BR>
	<STRONG>Gonadotropin-Releasing Hormone Receptors</STRONG><BR>
	
		
			Endocr. Rev.,
		
	
        
        April&nbsp;1,&nbsp;2004;
	25(2):
	235 - 275.
<BR>
<A HREF="http://edrv.endojournals.org/cgi/content/abstract/25/2/235">[Abstract]</A>

<A HREF="http://edrv.endojournals.org/cgi/content/full/25/2/235">[Full Text]</A>
<A HREF="http://edrv.endojournals.org/cgi/reprint/25/2/235">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	V. D. Nair and S. C. Sealfon<BR>
	<STRONG>Agonist-specific Transactivation of Phosphoinositide 3-Kinase Signaling Pathway Mediated by the Dopamine D2 Receptor</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        November&nbsp;21,&nbsp;2003;
	278(47):
	47053 - 47061.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/278/47/47053">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/278/47/47053">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/278/47/47053">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.brjpharmacol.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.brjpharmacol.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.brjpharmacol.org"><IMG ALT="Br. J. Pharmacol." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/brjpharmacol.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	F. Bellucci, S. Meini, P. Cucchi, C. Catalani, W. Reichert, S. Zappitelli, L. Rotondaro, L. Quartara, A. Giolitti, and C. A. Maggi<BR>
	<STRONG>A different molecular interaction of bradykinin and the synthetic agonist FR190997 with the human B2 receptor: evidence from mutational analysis</STRONG><BR>
	
		
			Br. J. Pharmacol.,
		
	
        
        October&nbsp;3,&nbsp;2003;
	140(3):
	500 - 506.
<BR>
<A HREF="http://www.brjpharmacol.org/cgi/content/abstract/140/3/500">[Abstract]</A>

<A HREF="http://www.brjpharmacol.org/cgi/content/full/140/3/500">[Full Text]</A>
<A HREF="http://www.brjpharmacol.org/cgi/reprint/140/3/500">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	C. Prioleau, I. Visiers, B. J. Ebersole, H. Weinstein, and S. C. Sealfon<BR>
	<STRONG>Conserved Helix 7 Tyrosine Acts as a Multistate Conformational Switch in the 5HT2C Receptor. IDENTIFICATION OF A NOVEL "LOCKED-ON" PHENOTYPE AND DOUBLE REVERTANT MUTATIONS</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        September&nbsp;27,&nbsp;2002;
	277(39):
	36577 - 36584.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/277/39/36577">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/277/39/36577">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/277/39/36577">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://molpharm.aspetjournals.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://molpharm.aspetjournals.org"><IMG ALT="Mol Pharmacol" WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/molpharm.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	D. S. Kang and L. M. F. Leeb-Lundberg<BR>
	<STRONG>Negative and Positive Regulatory Epitopes in the C-Terminal Domains of the Human B1 and B2 Bradykinin Receptor Subtypes Determine Receptor Coupling Efficacy to G9/11-Mediated Phospholipase Cbeta  Activity</STRONG><BR>
	
		
			Mol. Pharmacol.,
		
	
        
        August&nbsp;1,&nbsp;2002;
	62(2):
	281 - 288.
<BR>
<A HREF="http://molpharm.aspetjournals.org/cgi/content/abstract/62/2/281">[Abstract]</A>

<A HREF="http://molpharm.aspetjournals.org/cgi/content/full/62/2/281">[Full Text]</A>
<A HREF="http://molpharm.aspetjournals.org/cgi/reprint/62/2/281">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	
		
 
 
 <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" WIDTH="600">
 
 <TR BGCOLOR="#D9D4C5">
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="25"><IMG ALT="" WIDTH="25" HEIGHT="5" SRC="/icons/spacer.gif"><BR>
 
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 
 <TD ALIGN="CENTER" VALIGN="TOP" WIDTH="61" NOWRAP>
 	<A HREF="http://www.jbc.org"><IMG ALT="Home page" WIDTH="59" HEIGHT="80" VSPACE="5" BORDER="1" SRC="http://www.jbc.org/portal_imgs/search_result.gif"></A><BR>
 </TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 <TD VALIGN="TOP" WIDTH="499" NOWRAP>
 <A HREF="http://www.jbc.org"><IMG ALT="J. Biol. Chem." WIDTH="450" HEIGHT="16" VSPACE="5" BORDER="0" SRC="/icons/shared/searchall/journals/jbc.gif"><IMG ALT="Home page" BORDER="0" WIDTH="49" HEIGHT="16" VSPACE="5" SRC="/icons/shared/search/homelink.gif"></A><BR>
 <FONT SIZE="-1" FACE="verdana,arial,helvetica">
	Z.-G. Gao, A. Chen, D. Barak, S.-K. Kim, C. E. Muller, and K. A. Jacobson<BR>
	<STRONG>Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor</STRONG><BR>
	
		
			J. Biol. Chem.,
		
	
        
        May&nbsp;24,&nbsp;2002;
	277(21):
	19056 - 19063.
<BR>
<A HREF="http://www.jbc.org/cgi/content/abstract/277/21/19056">[Abstract]</A>

<A HREF="http://www.jbc.org/cgi/content/full/277/21/19056">[Full Text]</A>
<A HREF="http://www.jbc.org/cgi/reprint/277/21/19056">[PDF]</A>
<BR><IMG ALT="" WIDTH="499" HEIGHT="1" SRC="/icons/spacer.gif">
 </FONT></TD>
 <TD WIDTH="5"><IMG ALT="" WIDTH="5" HEIGHT="5" SRC="/icons/spacer.gif"></TD>
 </TR>
 <TR><TD COLSPAN="6"><HR NOSHADE SIZE="1" WIDTH="600" COLOR="#828282" ALIGN="LEFT"></TD></TR>
 </TABLE>

	











<BR CLEAR=ALL>


	
	 
		
		  
			
	
		<table class="content_box_outer_table"
		 
			
				
					
						align="right"
					
				
			
		>
			<tr>
			<td>
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				
				<strong><a href="/cgi/content/abstract/276/44/41100">
				Abstract</a></strong>
				 					<img alt="" width="32" height="7" border="0" src="/icons/shared/toc/free.gif">
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	

	
	
	

	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		
		
		
			
				
				
					<a href="/cgi/reprint/276/44/41100">
		<strong>Full Text</strong> (PDF)</a>
				
			
		
		</strong>
		</td></tr>
	
	

	
	
	

	
	
	

	
	





	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			

			
	
	

	
		
	









	
		
	
		
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item"><strong>
			All Versions of this Article:<br>
		
			
					276/44/41100
				
		&nbsp;&nbsp;&nbsp;<font color="#006699"><em>most recent</em></font><br>
	

	
		
		
			<a href="/cgi/content/short/M104875200v1">
					M104875200v1</a>
			
		</strong></td></tr>
	

	





	

	 

	

	
	
		  
    

	







		
	
		
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=citedby&addAlert=cited_by&saveAlert=no&cited_by_criteria_resid=jbc;276/44/41100&return_type=article&return_url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F44%2F41100">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/ctalert?alertType=correction&addAlert=correction&saveAlert=no&correction_criteria_value=276/44/41100&return_type=article&return_url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F44%2F41100">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		










			
		
			
			
			
				
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
					<strong><a href="/cgi/citemap?id=jbc;276/44/41100">
					Citation Map</a></strong>
				</td></tr>
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/mailafriend?url=http%3A%2F%2Fwww.jbc.org%2Fcgi%2Fcontent%2Ffull%2F276%2F44%2F41100&title=Control+of+Conformational+Equilibria+in+the+Human+B2+Bradykinin+Receptor.+MODELING+OF+NONPEPTIDIC+LIGAND+ACTION+AND+COMPARISON+TO+THE+RHODOPSIN+STRUCTURE">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

		
		



			
			
			
		
	

		
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
		<strong>
		<a href="/cgi/search?qbe=jbc;M104875200&journalcode=jbc&minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11495910&link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
	

		
		
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
			<strong><a href="/cgi/citmgr?gca=jbc;276/44/41100">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	


	

	

		


	
	
	
		

			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><A HREF="/misc/Copyright_Permission.shtml">Copyright Permissions</a></strong>
			</td></tr>
		

	

	






	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt="" width="200" height="1" src="/icons/spacer.gif"></td></tr>
			
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
				<strong><a href="/cgi/external_ref?access_num=11495910&link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Marie+J&link_type=AUTHORSEARCH">
							Articles by Marie, J.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td width="4" class="content_box_arrow" valign="top"><img alt="" width="4" height="11" border="0" src="/icons/shared/misc/arrowTtrim.gif"></td><td class="content_box_item">
							<strong><a target="_blank" href="/cgi/external_ref?access_num=Bonnafous+JC&link_type=AUTHORSEARCH">
							Articles by Bonnafous, J.-C.</a></strong>
						</td></tr>
				
			
		

		
	






	






	
		

	

		
			
		











	




	</td></tr></table>
</td></tr></table> 

					
					
	

<BR CLEAR=ALL>








	
	<P>
	<HR NOSHADE ALIGN="LEFT" WIDTH="450" SIZE="1">
	
	<TABLE CELLPADDING="2" CELLSPACING="2" WIDTH="450">
	<TR>
		<TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">HOME</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/help/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">HELP</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/cgi/feedback"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">FEEDBACK</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/subscriptions/"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">SUBSCRIPTIONS</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/contents-by-date.0.shtml"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">ARCHIVE</FONT></A></TD>
	    <TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/search.dtl"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">SEARCH</FONT></A></TD>
	    


<TD ALIGN="CENTER" VALIGN="MIDDLE" BGCOLOR="#006699" NOWRAP><A TARGET="_top" STYLE="text-decoration: none" HREF="/content/vol276/issue44/index.shtml"><FONT SIZE="-2" COLOR="#FFFFFF" FACE="arial,helvetica">TABLE OF CONTENTS</FONT></A></TD>




	</TR>
	</TABLE>
	
	


	
<TABLE CELLPADDING="2" CELLSPACING="2" BORDER="0">
<TR>
	<TD BGCOLOR="#006699" ALIGN="CENTER" NOWRAP>&nbsp;<A STYLE="text-decoration:none" HREF="http://www.asbmb.org/"><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">All ASBMB Journals</A></STRONG>&nbsp;</TD>
	<TD BGCOLOR="#CC0000" ALIGN="CENTER" NOWRAP>&nbsp;<A STYLE="text-decoration:none" HREF="http://www.mcponline.org/"><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">Molecular and Cellular Proteomics</A></STRONG>&nbsp;</TD>
</TR><TR>
	<TD BGCOLOR="#0099FF" ALIGN="CENTER" NOWRAP>&nbsp;<A STYLE="text-decoration:none" HREF="http://www.jlr.org/"><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">Journal of Lipid Research</A></STRONG>&nbsp;</TD>
	<TD BGCOLOR="#003F77" ALIGN="CENTER" NOWRAP>&nbsp;<A STYLE="text-decoration:none" HREF="http://www.bambed.org/"><STRONG><FONT SIZE="-2" FACE="verdana,arial,helvetica" COLOR="#FFFFFF">Biochemistry and Molecular Biology Education</A></STRONG>&nbsp;</TD>
</TR>
</TABLE>

	<FONT SIZE="-1"><STRONG><A TARGET="_top" HREF="/misc/terms.shtml">Copyright &copy; 2001 by the American Society for Biochemistry and Molecular Biology.</A></STRONG></FONT>
	


</BODY>
</HTML>

<script language="JavaScript">
<!--
var SymRealOnLoad;
var SymRealOnUnload;

function SymOnUnload()
{
  window.open = SymWinOpen;
  if(SymRealOnUnload != null)
     SymRealOnUnload();
}

function SymOnLoad()
{
  if(SymRealOnLoad != null)
     SymRealOnLoad();
  window.open = SymRealWinOpen;
  SymRealOnUnload = window.onunload;
  window.onunload = SymOnUnload;
}

SymRealOnLoad = window.onload;
window.onload = SymOnLoad;

//-->
</script>

